Methods for modulating cell proliferation with the combined use of SOS1 inhibitors and osimertinib and / or MET inhibitors for cancer treatment

Combining SOS1 inhibitors with osimertinib and/or MET inhibitors addresses resistance in EGFR-mediated cancers by synergistically reducing proliferation, offering effective treatment for EGFR exon 20 insertions and other mutations.

JP2026539025APending Publication Date: 2026-11-19KUMQUAT BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026523479
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-14
Filing Date
2024-10-24
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing treatments for EGFR-mediated cancers, particularly those with exon 20 insertions, face resistance to first and second-generation inhibitors, necessitating a need for long-term therapeutic solutions.

Method used

Combining SOS1 inhibitors with osimertinib and/or MET inhibitors to downregulate EGFR signaling and synergistically reduce cancer cell proliferation, using specific compounds like BI-3406 or formula (I-1) in various formulations.

Benefits of technology

The combination achieves a synergistic effect of at least 0.1 in reducing cancer cell proliferation, overcoming resistance and providing therapeutic benefits in EGFR-mediated cancers, including non-small cell lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539025000001_ABST
    Figure 2026539025000001_ABST
Patent Text Reader

Abstract

This disclosure provides compounds and pharmaceutically acceptable salts thereof, as well as methods for using them. These compounds and methods have a wide range of applications as therapeutic agents, diagnostic tools, and research tools. In particular, the compositions and methods of this disclosure, when used in combination with one or more other therapeutic agents, are useful for reducing the signaling output of oncogenic proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Cross-reference of related applications This application claims the interests of U.S. Provisional Patent Application No. 63 / 593,222 filed on 25 October 2023, U.S. Provisional Patent Application No. 63 / 572,068 filed on 29 March 2024, and U.S. Provisional Patent Application No. 63 / 683,193 filed on 14 August 2024, which are incorporated herein by reference in their entirety.

[0002] Sequence List This application includes a sequence listing submitted electronically in XML format, the sequence being incorporated herein by reference in its entirety. The XML copy, created on October 21, 2024, is named 56690_775_601_SL.xml and has a size of 4,097 bytes.

[0003] The ErbB family of receptor tyrosine kinases includes EGFR (HER1 / ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4), each of which is a mediator of normal cell proliferation and development. In particular, EGFR phosphorylation activates downstream signaling pathways involved in cell proliferation, angiogenesis, apoptosis, and metastasis, including the PI3K / AKT / mTOR, STAT, and RAS / MAPK pathways. EGFR overexpression is frequently observed in a variety of tumors, including cancers of the brain, breast, cervix, colon, esophagus, head and neck, kidney, lung, ovary, and stomach.

[0004] EGFR mutations are the most common genetic alterations in non-small cell lung cancer (NSCLC), detected in over 40% of NSCLC cases in Asia and over 10% in North America and Europe. L858R point mutations and exon 19 deletions are often referred to as classic EGFR-activating mutations and result in constitutive activation of EGFR and downstream signaling pathways, particularly in NSCLC. These variants exhibit greater affinity for ATP-competitive EGFR inhibitors, which, combined with increased tumor cell dependence on EGFR signaling, creates a large therapeutic window for EGFR inhibition, making them effective treatments for NSCLC patients with classic EGFR mutations. However, certain exon 20 mutations, including T790M and exon 20 insertions, activate EGFR while resulting in tumor resistance to first and second-generation EGFR inhibitors targeting classic EGFR mutations, such as gefitinib, erlotinib, and afatinib. Lung cancer is a leading cause of cancer-related death worldwide, partly due to these resistance mechanisms. In 2023, an estimated 238,000 people in the United States were diagnosed with lung and bronchial cancer, and approximately 127,000 people were expected to die from these cancers.

[0005] Osimertinib is a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for adjuvant therapy and treatment of metastatic NSCLC patients with EGFR-activating mutations (exon 19 deletion and exon 21 L858R mutation). It is also approved for NSCLC patients with exon 20 T790M mutations that have progressed after EGFR therapy. Although osimertinib improved clinical outcomes in these patients, their tumors eventually progressed, and the efficacy of subsequent treatment was limited. See V.Di Noia, et al., ESMO Open, 2021, 6(6), 100280 (doi:10.1016 / j.esmoop.2021.100280).

[0006] Son of Sevenless 1 (SOS1) is a homolog of SOS2 in mammalian cells and acts as a guanine nucleotide exchange factor (GEF) to promote the release of inactive GDP from RAS-family proteins, enabling GTP binding. SOS1 is involved in cancer through its ability to activate signaling of RAS-family proteins. SOS1 interacts with the adapter protein Grb2, and the resulting SOS1 / Grb2 complex binds to activated / phosphorylated receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3). SOS1 is also recruited to other phosphorylated cell surface receptors such as the T cell receptor (TCR), B cell receptor (BCR), and monocyte colony-stimulating factor receptor. By localizing SOS1 to the cell membrane and being in close proximity to RAS-family proteins, SOS1 promotes the activation of RAS-family proteins. Activation of RAS-family proteins by SOS1 may also be mediated by the interaction between SOS1 and the BCR-ABL oncoprotein, which is frequently observed in chronic myeloid leukemia. [Overview of the project]

[0007] To address the long-standing need to obtain long-term therapeutic benefits for EGFR-mediated diseases, including various types of cancer, there is an urgent need to identify relevant monotherapies and combination therapies. This invention addresses these needs and simultaneously provides related advantages.

[0008] In certain embodiments, the Disclosure provides a method for reducing the proliferation of cancer cells containing an epidermal growth factor receptor (EGFR) exon 20 insertion, administered to cells by (a) before, concurrently with, or after, the administration of (b). In some embodiments, the cancer cells are non-small cell lung cancer cells. In certain embodiments, the Disclosure provides a method for downregulating EGFR signaling output in a plurality of non-small cell lung cancer cells, comprising (i) evaluating the EGFR mutation status in a biological sample containing nucleic acids from a subject, and (ii) administering, if an EGFR exon 20 insertion is detected in the sample, (a) an effective dose of an SOS1 inhibitor and (b) an effective dose of osimertinib, administered by (a) before, concurrently with, or after, the administration of (b).

[0009] In certain embodiments, the Disclosure provides a method for treating cancer in a subject, the method comprising administering (a) an SOS1 inhibitor and (b) a MET inhibitor to the subject, wherein (a) is administered before, simultaneously with, or after the administration of (b). In some embodiments, the cancer is an EGFR-mediated cancer. In some embodiments, the cancer exhibits MET amplification. In some embodiments, the MET inhibitor is savolitinib. In some embodiments, the method further comprises administering (c) an additional agent or additional therapy. In some embodiments, the additional agent is an EGFR inhibitor. In some embodiments, the EGFR inhibitor is selected from gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, poziotinib, mobocertinib, diparereltinib, sambozertinib, BAY-2927088, BLU-451, BLU-945, STX-721, and zolifertinib. In some embodiments, the EGFR inhibitor is osimertinib. In some embodiments, additional therapies are selected from surgery, cell therapy, chemotherapy, and radiation. In some embodiments, the administration of (a) and (b) synergistically reduces cancer cell proliferation with a synergistic effect value of at least 0.1, as confirmed by the Bliss independence criterion.

[0010] In certain embodiments, the Disclosure provides a method for treating EGFR-mediated cancer in a subject, the method comprising administering (a) an SOS1 inhibitor and (b) osimertinib to the subject, wherein (a) is administered before, concurrently with, or after the administration of (b), and the administrations of (a) and (b) synergistically reduce cancer cell proliferation by a synergistic effect value of at least 0.1, as confirmed by the Bliss independence criterion. In some embodiments, the synergistic effect value is confirmed by the Bliss independence criterion according to the following formula: Y AB,O -Y AB,P , where Y AB,O This is the measured value of the rate of inhibition of cancer cell proliferation by applying (a) and (b), which include (a) at dose A and (b) at dose B, and Y AB,Pis the predicted value of the cancer cell proliferation inhibition rate by the application of (a) and (b), wherein (a) is at dose A and (b) is at dose B, where Y AB,P =Y A +Y B -Y A Y B , and Y A is the measured value of the cancer cell proliferation inhibition rate when (a) is applied alone at dose A, Y B is the measured value of the cancer cell proliferation inhibition rate when (b) is applied alone at dose B, Y A Y B is the product of Y A and Y B . In some embodiments, the synergistic value is at least 0.4, such as at least 1 or at least 5.

[0011] In practicing any of the methods of the present disclosure, the SOS1 inhibitor may be selected from BI-3406, MRTX0902, BAY293, RMC-5845, and BI-1701963. In some embodiments, the SOS1 inhibitor is a compound of formula (I-1): [Chemical Formula] or a pharmaceutically acceptable salt or solvate thereof, wherein [Chemical Formula] is selected from C 5-7 carbocycle and 5- to 7-membered heterocycle, each of which is optionally substituted with one or more R 11 , [Chemical Formula] is absent, or selected from C 3-8 carbocycle and 3- to 8-membered heterocycle, each of which is optionally substituted with one or more R 11a , L 1 is selected from a bond, C 1-6 alkylene, and C 1-6 haloalkylene, L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, W 3 N(R) 3b ), N, C(R 3 ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected, W 5 N(R) 5b ), N, and C(R 5 ) are selected from, W 6 C(R 6 ) and C(O) are selected, W 7 C(R 7 ) and R 1 is one or more R 11c C is optionally replaced by 1-3 It is alkyl, R 8 Hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 , -S(O)2R 15 , -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 , -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, and 3-10 membered heterocycle are each independently optionally substituted with 1, 2, or 3 R 20 , R 3 , R 4 , R 5 , R 6 , and R 7 each represent a bond to L 2 , hydrogen, halogen, -CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11 and R 11a In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15, -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11c In each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) were selected independently of, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 , and R 13 Together with the nitrogen atom to which they bond, they form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl, and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22)(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with 1, 2, or 3 groups independently selected from alkyl groups, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with 1, 2, or 3 groups independently selected from alkyl groups, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0012] When performing any of the methods of this disclosure, the cancer may be a lung cancer, such as non-small cell lung cancer. In some embodiments, the cancer cells of interest contain an EGFR mutation. In some embodiments, the EGFR mutation is selected from L858R mutations, T790M mutations, exon 19 deletions, and exon 20 insertions, such as exon 20 insertions. In some embodiments, the cancer cells of interest contain MET overexpression. In some embodiments, the cancer cells of interest contain MET amplification. In some embodiments, the subjects exhibit cancer recurrence. In some embodiments, the subjects have been previously treated with platinum-based chemotherapy. In some embodiments, the subjects have been previously treated with a tyrosine kinase inhibitor (TKI) against EGFR before administering (a) and (b). In some embodiments, the subject has been previously treated with a non-exon 20 insertion EGFR TKI such as gefitinib, erlotinib, afatinib, razeltinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, BLU-945, or zolifertinib. In some embodiments, the subject has been previously treated with an EGFR exon 20 insertion TKI such as poziotinib, mobocertinib, amibantamab, diparereltinib, sambozertinib, BAY-2927088, BLU-451, or STX-721. In some embodiments, the subject exhibits resistance or intolerance to the TKI. Resistance to TKIs may be characterized by one or more changes selected from (1) cancer progression, (2) EGFR gene mutation, (3) loss of EGFR T790M mutation, (4) EGFR gene amplification, (5) MET amplification, (6) HER2 amplification, (7) RAS-MAPK pathway activation, (8) PI3K pathway activation, (9) cell cycle gene alteration, (10) oncogenic fusion, (11) histological transformation, and (12) phenotypic transformation.

[0013] The methods described herein may further include (c) administering an additional agent or additional therapy. In some embodiments, the additional agent is selected from EGFR TKIs other than osimertinib, immunomodulators, anti-nausea agents, antiemetics, analgesics, steroids, and chemotherapeutic agents. In some embodiments, the additional agent is selected from immunomodulators, cytokine blockers, and checkpoint immunoblockers. In some embodiments, the additional agent is selected from anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-PD-1 antibodies, anti-LAG3 antibodies, anti-TIM3 antibodies, and combinations thereof. In some embodiments, the additional agent is a MET inhibitor such as savolitinib. In some embodiments, the additional therapy is selected from surgery, cell therapy, chemotherapy, and radiation.

[0014] When performing any of the methods of the present disclosure, administration of (a) and (b) may reduce the incidence of one or more adverse events associated with osimertinib. In some embodiments, the adverse events are selected from diarrhea, rash, nausea, stomatitis, vomiting, paronychia, fatigue, dry skin, loss of appetite, headache, anemia, pneumonia, pruritus, constipation, and cough. In some embodiments, the adverse events are selected from diarrhea, rash, nausea, dry skin, and paronychia.

[0015] When performing any of the methods of this disclosure, the administration of (a) and (b) may exhibit a synergistic effect. In some embodiments, the synergistic effect is characterized by a synergistic value of at least 0.05 as confirmed by the Bliss independence criterion. In some embodiments, one or both of (a) and (b) are administered at or below a therapeutic dose, but a therapeutic effect at least comparable to that of (a) or (b) administered at a therapeutically effective dose alone is achieved. In some embodiments, osimertinib is administered at a dose less than approximately 25% of the standard monotherapy dose. In some embodiments, (a) and (b) are administered in the same formulation. In some embodiments, (a) and (b) are administered in separate formulations.

[0016] In certain embodiments, the Disclosure provides a kit for use in reducing the proliferation of cancer cells containing epidermal growth factor receptor (EGFR) exon 20 insertions, the kit comprising (1) a composition comprising an SOS1 inhibitor of formula (I-1), (2) a composition comprising osimertinib, and (3) instructions for using the compositions of (1) and (2). In some embodiments, the SOS1 inhibitor and osimertinib are formulated in the same unit dosage form. In some embodiments, the SOS1 inhibitor and osimertinib are formulated in different unit dosage forms.

[0017] In certain embodiments, the Disclosure provides a pharmaceutical composition comprising (i) an SOS1 inhibitor of formula (I-1) or a pharmaceutically acceptable salt or solvate thereof, (ii) osimertinib, and (iii) a pharmaceutically acceptable excipient. In certain embodiments, the Disclosure provides a method for treating EGFR-mediated cancer in a subject, the method comprising administering to the subject a pharmaceutical composition comprising (i) an SOS1 inhibitor of formula (I-1) or a pharmaceutically acceptable salt or solvate thereof, (ii) osimertinib, and (iii) a pharmaceutically acceptable excipient. When performing any of the methods of the Disclosure, the subject may be a naive subject that has not been treated with a TKI against EGFR prior to administration of (a) and (b).

[0018] Reference All publications, patents, and patent applications referenced herein are incorporated by reference to the same extent as any individual publication, patent, or patent application is specifically and individually indicated to be incorporated by reference. [Brief explanation of the drawing]

[0019] Novel features of the present invention are described in detail in the appended claims. A deeper understanding of the characteristics and advantages of the present invention will be obtained by referring to the following detailed description of exemplary embodiments in which the principles of the present invention are utilized, and to the following appended drawings (also referred to herein as "Figures").

[0020] [Figure 1A] Figure 1A shows the degree of inhibition of Ba / F3-EGFR_Ex20_ASV insertion cell proliferation when treated with (i) the SOS1 inhibitor of the present disclosure (e.g., compound A at various concentrations) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii) at various concentrations. [Figure 1B] Figure 1B shows the degree of synergistic effect across all drug combinations in Figure 1A, calculated using the BLISS independent model. [Figure 2A] Figure 2A shows the degree of inhibition of Ba / F3-EGFR_L858R / T790M cell proliferation when treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A at various concentrations) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii) at various concentrations. [Figure 2B] Figure 2B shows the degree of synergistic effect across all combinations shown in Figure 2A, calculated using the BLISS independent model. [Figure 3A] Figure 3A shows the degree of inhibition of proliferation of PC9-EGFR Ex19 E746_A750-deficient cells when treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A at various concentrations) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii) at various concentrations. [Figure 3B] Figure 3B shows the degree of synergistic effect for the entire combination shown in Figure 3A, calculated using the BLISS independent model. [Figure 4A] Figure 4A shows the degree of inhibition of H1975-EGFR L858R / T790M cell proliferation when treated with (i) the SOS1 inhibitor of the present disclosure (e.g., compound A at various concentrations) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii) at various concentrations. [Figure 4B] Figure 4B shows the degree of synergistic effect for the entire combination shown in Figure 4A, calculated using the BLISS independent model. [Figure 5]Figure 5 shows Western blots illustrating the degree of EGFR signaling inhibition, as assessed by the level of phosphorylated ERK (p-ERK), in H1975-EGFR L858R / T790M cells treated for 24 hours with (i) osimertinib alone or (ii) osimertinib in combination with the SOS1 inhibitor of this disclosure (e.g., compound A) at a specified concentration (nM). The data show that the combination of the SOS1 inhibitor of this disclosure and osimertinib prevents the refractory and residual p-ERK signaling observed with osimertinib monotherapy (indicated by arrows). Such synergistic effects result in greater apoptosis (increased cleavage of PARP). [Figure 6] Figure 6 shows the results of a study in which mice with Ba / F3-EGFR-V769_D770insASV allograft tumors were treated with (i) an SOS1 inhibitor of the Disclosure (e.g., compound A) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii). The results show that the SOS1 inhibitors disclosed herein, in combination with osimertinib, synergistically reduce tumor volume in the tumor model. [Figure 7] Figure 7 shows the results of a study in which LU0858 mice (a xenograft (PDX) model derived from NSCLC patients exhibiting the EGFR-L858R mutation with MET amplification) were treated with the vehicle or the SOS1 inhibitors disclosed herein (e.g., compound A). The results demonstrate that the SOS1 inhibitors disclosed herein are effective alone in reducing tumor volume in EGFR-mediated lung cancer, particularly in MET-amplified lung cancer. [Figure 8] Figure 8 shows the results of a study in which LU0387 mice (an NSCLC PDX model exhibiting the EGFR-exon 20 D770_N771_insNPH mutation) were treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii). The results show that the SOS1 inhibitors disclosed herein, in combination with osimertinib, synergistically reduce the tumor volume of EGFR-exon 20 insertion tumors. [Figure 9]Figure 9 shows the results of a study in which mice with Ba / F3-EGFR-L858 / T790M allograft tumors were treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii). The results show that the SOS1 inhibitors disclosed herein, in combination with osimertinib, synergistically reduce tumor volume in the tumor model. [Figure 10] Figure 10 shows the results of a study in which mice carrying H1975 xenograft tumors (NSCLC models exhibiting the EGFR L858R / T790M mutation) were treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii). The results show that the SOS1 inhibitors disclosed herein, in combination with osimertinib, synergistically reduce the tumor volume of the tumor model. [Figure 11] Figure 11 shows the results of a study in which mice having a squamous epithelial NSCLC PDX model exhibiting the EGFR-exon 20 D772_N773insDNP mutation were treated with (i) the SOS1 inhibitor of this disclosure (e.g., compound A) alone, (ii) osimertinib alone, or (iii) a combination of (i) and (ii). The results show that the SOS1 inhibitors disclosed herein, in combination with osimertinib, synergistically reduce the tumor volume of the tumor model. [Modes for carrying out the invention]

[0021] The practices of some embodiments disclosed herein employ prior art in immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, unless otherwise indicated, within the scope of the art of those skilled in the art. See, for example, Sambrook and Green, Molecular Cloning: A Laboratory Manual, 4th Edition (2012); the series Current Protocols in Molecular Biology (FM Ausubel, et al. eds.); the series Methods In Enzymology (Academic Press, Inc.); PCR 2: A Practical Approach (MJ MacPherson, BD Hames and GR Taylor eds. (1995)); Antibodies, A Laboratory Manual (Harlow and Lane, eds. (1988)); and Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, 6th Edition (RI Freshney, ed. (2010)).

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to whom this disclosure belongs. If there are multiple definitions of a term herein, the definition in this section shall prevail. All patents, patent applications, publications, and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referenced herein are incorporated by reference. Chemical structures are named herein in accordance with the IUPAC agreement as implemented in the ChemDraw® software (Perkin Elmer, Inc., Cambridge, MA). Section headings used herein are merely structural and should not be construed as limiting the subject matter described. Where used herein and in the claims, the singular forms “a,” “an,” and “the” also include plural references unless the context clearly indicates otherwise.

[0023] For example, when used herein to refer to measurable values ​​such as quantity or duration, "approximately" is intended to include a variation of ±10% of the given number or value.

[0024] When used in conjunction with chemical parts such as alkyl, alkenyl, or alkynyl, "C x-y " or "C x -C y The term "C" means a group containing x to y carbon atoms in the chain. For example, "C x-y The term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain and branched-chain alkyl groups, that contain x to y carbon atoms in their chain.

[0025] "Alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including linear and branched alkyl groups. Alkyl groups consist of 1 to 12 carbon atoms (for example, C 1-12 Alkyl), for example, 1 to 8 carbon atoms (C 1-8 Alkyl) or 1 to 6 carbon atoms (C 1-6The molecule may contain alkyl groups. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl. The alkyl group is attached to the rest of the molecule by a single bond. Unless otherwise expressly stated herein, the alkyl group may be optionally substituted with one or more substituents, such as those described herein.

[0026] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.

[0027] "Alkenyl" refers to a substituted or unsubstituted hydrocarbon group that contains a linear or branched alkenyl group containing at least one double bond. An alkenyl group has 2 to 12 carbon atoms (for example, C 2-12 Alkenyls), for example, 2 to 8 carbon atoms (C 2-8 Alkenyl) or 2-6 carbon atoms (C) 2-6 The material may contain an alkenyl group. Examples of alkenyl groups include ethenyl (i.e., vinyl), propa-1-enyl, buta-1-enyl, penta-1-enyl, and penta-1,4-dienyl. Unless otherwise specified herein, the alkenyl group may be optionally substituted with one or more substituents, such as those described herein.

[0028] "Alkynyl" refers to a substituted or unsubstituted hydrocarbon group containing a linear or branched alkynyl group with at least one triple bond. An alkynyl group has 2 to 12 carbon atoms (e.g., C 2-12 Alkynyl), for example, 2 to 8 carbon atoms (C 2-8 Alkynyl) or 2-6 carbon atoms (C) 2-6The material may contain an alkynyl group. Examples of alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, and hexynyl. Unless otherwise specified herein, the alkynyl group may be optionally substituted with one or more substituents, such as those described herein.

[0029] "Alkylene" or "alkylene chain" consists of 1 to 12 carbon atoms (for example, C 1-12 Alkylenes), for example, 1 to 8 carbon atoms (C) 1-8 Alkylene) or 1 to 6 carbon atoms (C) 1-6 This refers to substituted or unsubstituted divalent saturated hydrocarbon groups, including linear alkylene groups and branched alkylene groups containing alkylene. Examples of alkylene groups include methylene, ethylene, propylene, and n-butylene. Similarly, "alkenylene" and "alkynylene" refer to the alkylene groups defined above, each containing one or more carbon-carbon double or triple bonds. The bonding sites of the alkylene, alkenylene, or alkynylene chains to the rest of the molecule may be via one carbon or any two carbons of the chain. Unless otherwise specified herein, the alkylene, alkenylene, or alkynylene groups are optionally substituted with one or more substituents, such as those described herein.

[0030] "Heteroalkyl," "heteroalkenyl," and "heteroalkynyl" refer to substituted or unsubstituted alkyl, alkenyl, and alkynyl groups, respectively, in which one or more carbon atoms, e.g., 1, 2, or 3, are substituted with heteroatoms such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may be optionally oxidized, and any nitrogen heteroatom may be optionally quaternized. Where a numerical range is specified, it refers to the total chain length. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms. Connection to the rest of the molecule may occur via any heteroatoms or carbons in the heteroalkyl chain, heteroalkenyl chain, or heteroalkynyl chain. Unless otherwise specified herein, heteroalkyl groups, heteroalkenyl groups, or heteroalkynyl groups are optionally substituted with one or more substituents, such as substituents described herein.

[0031] "Heteroalkylene," "heteroalkenylene," and "heteroalkylynylene" refer to substituted or unsubstituted alkylene, alkenylene, and alkylynylene groups, respectively, in which one or more carbon atoms, e.g., 1, 2, or 3, are substituted with heteroatoms such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may be optionally oxidized, and any nitrogen heteroatom may be optionally quaternized. If a numerical range is specified, it refers to the total chain length. For example, a 3- to 8-membered heteroalkylene group has a chain length of 3 to 8 atoms. Bonding sites of a heteroalkylene, heteroalkenylene, or heteroalkylynylene chain to the rest of the molecule may be via one heteroatom or one carbon in the heteroalkylene, heteroalkenylene, or heteroalkylynylene chain, or via any two heteroatoms, any two carbons, or any one heteroatom and any one carbon. Unless otherwise specified herein, heteroalkylene, heteroalkenylene, or heteroalkylynylene groups are optionally substituted with one or more substituents, such as substituents described herein.

[0032] A "carbon ring" refers to a saturated, unsaturated, or aromatic ring in which each atom of the ring is a carbon atom. 3-10 Monocyclic ring, C 6-12 Bicyclic ring, C 6-12 Spirocyclic rings, and C 6-12 It may include a bridging ring. Each ring in the bicyclic carbon ring may be selected from saturated, unsaturated, and aromatic rings. In some embodiments, the carbon ring is C 6-10 C such as aryl 6-12 It is an aryl group. In some embodiments, the carbon ring is C 6-12 It is a cycloalkyl group. In some embodiments, the carbon ring is C 6-12The group is a cycloalkenyl group. In exemplary embodiments, an aromatic ring, such as phenyl, may be condensed to a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated, and aromatic bicyclic rings is included in the definition of a carbocyclic ring, as long as the valency allows. Exemplary carbocyclic rings include cyclopentyl, cyclohexyl, cyclohexenyl, adamantly, phenyl, indanyl, and naphthyl. Unless otherwise specified herein, carbocyclic rings are optionally substituted with one or more substituents, such as those described herein.

[0033] A "heterocycle" refers to a saturated, unsaturated, or aromatic ring containing one or more heteroatoms, e.g., one, two, or three heteroatoms selected from O, S, and N. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 6- to 12-membered spirocyclic rings, and 6- to 12-membered bridging rings. Each ring in a bicyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. Heterocycles may be bonded to the rest of the molecule via any atom of the heterocycle, such as a carbon or nitrogen atom of the heterocycle, as long as the valence allows. In some embodiments, the heterocycle is a 5- to 10-membered heteroaryl group, e.g., a 5 or 6-membered heteroaryl group. In some embodiments, the heterocycle is a 3- to 12-membered heterocycloalkyl group. In exemplary embodiments, the heterocycle, e.g., pyridyl, may be condensed to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridadinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, and quinolinyl. Unless otherwise specified herein, heterocycles are optionally substituted with one or more substituents, such as those described herein.

[0034] "Heteroaryl" refers to a 5- to 12-membered aromatic ring containing at least one heteroatom selected from O, S, and N, e.g., 1, 2, or 3 heteroatoms. As used herein, heteroaryl rings may be selected from monocyclic or bicyclic rings, including fused rings, spirocyclic rings, and bridging ring systems, where at least one of the rings in the ring system is aromatic. Heteroatoms in a heteroaryl may be optionally oxidized. They may be quaternized if one or more nitrogen atoms are present. Heteroaryls may be bonded to the rest of the molecule via any atom of the heteroaryl, such as the carbon or nitrogen atoms of the heteroaryl, as long as their valence allows. Examples of heteroaryl groups include, but are not limited to, azepinyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridadinyl, pyridazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, and thienyl groups. Unless otherwise specified herein, heteroaryls may be optionally substituted with one or more substituents, such as those described herein.

[0035] Unless otherwise stated, hydrogen atoms are implied in the structures depicted herein as necessary to satisfy the valence requirements.

[0036] Join or dashed line join [ka] A wavy line drawn across it [ka] The terms are used interchangeably herein to indicate the location where a bond break or bond occurs. For example, structure [ka] So, R 7 but, [ka] If it is 1-cyclopropyl-1-carbonnitrile, as in R 7 teeth, [ka] It can be described as follows.

[0037] The term “substitution” refers to a portion of a structure having substituents that substitute for hydrogen atoms on one or more carbon atoms or heteroatoms. It will be understood that “substitution” or “substituted with” implicitly implies that such substitution conforms to acceptable valencies of the substituted atom and substituent, and that the substitution results in a stable compound that does not undergo spontaneous transformation, such as rearrangement, cyclization, or elimination. As used herein, the term substitution is intended to include all acceptable substituents of an organic compound. In broad embodiments, acceptable substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. There may be one or more acceptable substituents for a given organic compound, and they may be the same or different. For the purposes of this disclosure, a heteroatom, such as nitrogen, may have any of the acceptable substituents of the organic compounds described herein that satisfy the valency of the heteroatom.

[0038] The compounds disclosed herein, for example, the compounds of formula (I), have one or more substituents selected from the following, for example, one, two, or three substituents: Halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10(Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 It is optionally replaced by, where C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with 1, 2, or 3 groups independently selected.

[0039] In some embodiments, the compounds disclosed herein, for example, the compound of formula (I), have one or more substituents selected from the following, for example, one, two, or three substituents: Halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR22 , and -OC(O)R 25 It is optionally replaced by, where C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , and -N(R 22 )(R 23 ) is optionally replaced by one, two, or three bases independently selected from, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with 1, 2, or 3 groups independently selected.

[0040] In some embodiments, the compounds disclosed herein, for example, the compound of formula (I), have one or more substituents selected from the following, for example, one, two or three substituents, halogen, oxo, =NH, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 It is optionally substituted with a carbon ring, a 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, where C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 The carbon rings, 3- to 10-membered heterocycles, and -CH2-(3- to 10-membered heterocycles) are optionally substituted with 1, 2, or 3 groups independently selected from halogens, oxo, =NH, -CN, -NO2, -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3.

[0041] It will be understood by those skilled in the art that, where appropriate, the substituents themselves may be substituted. Unless specifically stated as “unsubstituted,” references to chemical parts herein should be understood to include substituted variants. For example, references to “heteroaryl” groups or parts implicitly include both substituted and unsubstituted variants.

[0042] Where divalent substituents are specified herein by their conventional chemical formulas written from left to right, they are intended to encompass isomers resulting from describing the structure from right to left; for example, -CH2O- is intended to also encompass -OCH2-.

[0043] "Optional" or "optionally" means that the event or situation described afterward may or may not occur, and the description includes both cases where the event or situation occurs and cases where it does not. For example, an "optionally substituted" base may be either non-substituted or substituted.

[0044] The compounds of this disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, which include, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrous forms), conformational polymorphs, amorphous forms of the compounds, and mixtures thereof.

[0045] The compounds described herein may exhibit their natural isotopic abundance, or one or more atoms may be artificially enriched into specific isotopes having the same atomic number but with atomic masses or mass numbers different from those primarily found in nature. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are included within the scope of this disclosure. For example, hydrogen, 1 H (protium), 2 H (deuterium), and 3It has three natural isotopes represented by H (tritium). Protium is the most abundant isotope of hydrogen in nature. Deuterium enrichment may result in certain therapeutic benefits, such as increased in vivo half-life and / or exposure, or may provide compounds useful for investigating in vivo drug elimination and metabolic pathways. Examples of isotopes that may be incorporated into the compounds of this disclosure include: 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S, 36 Cl, and 18 F is one example, but is not limited to these. Of particular note are the compounds of formula (I) that are tritium or carbon-14 rich, which may be used in tissue distribution studies, and the compounds of this disclosure that are deuterium rich, for example, at the metabolic site, resulting in compounds with higher metabolic stability, and which may be used in positron emission topography (PET) studies, for example. 11 C, 18 F, 15 O, and 13 This is a compound of formula (I) that is rich in positron-emitting isotopes such as N. Isotopic-enriched compounds can be prepared by conventional techniques well known to those skilled in the art.

[0046] As used herein, the terms “formula,” “having a formula,” or “having a structure” are not intended to be limiting, but are used in the same manner as the term “including.” For example, if a structure is illustrated, it is understood that all stereoisomers and tautomers are included unless otherwise stated.

[0047] Certain compounds described herein contain one or more chiral centers, which can therefore give rise to enantiomers, diastereomers, and other stereoisomeric forms, the chiral centers of which may be defined as (R)- or (S)- from the viewpoint of absolute stereochemistry. In some embodiments, in order to optimize the therapeutic activity of the compounds of this disclosure, for example to treat cancer, it may be desirable for the carbon atoms to have a specific configuration (e.g., (R,R), (S,S), (S,R), or (R,S)) or to be enriched with stereoisomeric forms having such configurations. The compounds of this disclosure may be provided as racemic mixtures. Accordingly, this disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereomers), stereoisomer-enriched mixtures, etc., unless otherwise indicated. When a chemical structure is illustrated herein without any stereochemistry, it is understood that all possible stereoisomers are encompassed by such structure. Similarly, where a particular stereoisomer is shown or named herein, a person skilled in the art will understand, unless otherwise suggested, that small amounts of other stereoisomers may be present in the compositions of this disclosure, provided that the usefulness of the composition as a whole is not diminished by the presence of such other isomers. Individual stereoisomers can be obtained by a number of methods known in the art, including preparation using chiral synthons or chiral reagents, resolution using chiral chromatography with a suitable chiral stationary phase or support, or chemical conversion of them into diastereomers, separation of the diastereoisomers by conventional means such as chromatography or recrystallization, and then regeneration of the original stereoisomers.

[0048] Furthermore, where applicable, all cis-trans or E / Z isomers (geometric isomers), tautomers, and topoisomers of the compounds described herein are included in the scope of this disclosure unless otherwise specified.

[0049] The term “pharmaceutically acceptable” refers to a substance that, when used in the composition and method of the subject, is not biologically or otherwise unacceptable. For example, the term “pharmaceutically acceptable carrier” refers to a substance such as an adjuvant, excipient, flow enhancer, sweetener, diluent, preservative, pigment, colorant, flavor enhancer, surfactant, humectant, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that can be incorporated into a composition and administered to a patient without causing unacceptable biological effects or interacting with other components of the composition in an unacceptable manner. Such pharmaceutically acceptable substances typically include substances that meet the required standards of toxicological and manufacturing testing and have been identified as appropriate inactive ingredients by the U.S. Food and Drug Administration.

[0050] The terms “salt” and “pharmaceutically acceptable salt” refer to salts prepared from a base or acid. Pharmaceutically acceptable salts are suitable for administration to patients, such as mammals (e.g., salts that have acceptable mammalian safety for a given drug regimen). Salts can be formed from inorganic bases, organic bases, inorganic acids, and organic acids. Furthermore, if a compound contains both a basic moiety, such as an amine, pyridine, or imidazole, and an acidic moiety, such as a carboxylic acid or tetrazole, a zwitterion may be formed, which, as used herein, is included in the term “salt.” Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0051] "Pharmacologically acceptable acid addition salts" refer to salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, and phosphorous acid, which retain the biological effects and properties of the free base and are not biologically or otherwise undesirable. Salts formed with organic acids such as aliphatic mono and dicarboxylic acids, phenyl-substituted alkanes, hydroxyalkanoates, alkanedioates, aromatic acids, and aliphatic and aromatic sulfonic acids are also included, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Therefore, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, suberates, sebacinates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, and methanesulfonates. Amino acid salts such as alginates, glucons, and galacturons are also considered (see, for example, Berge SM et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared in some embodiments by contacting the free base form with a sufficient amount of the desired acid to produce the salt, according to methods and techniques familiar to those skilled in the art.

[0052] A "pharmaceutically acceptable base addition salt" refers to a salt that retains the biological efficacy and characteristics of a free acid and is not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to a free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed from metals or amines such as alkali metals and alkaline earth metals or organic amines. Examples of salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydravamin, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, and polyamine resins. See the book by Berge et al. cited above.

[0053] As used herein, “to treat” or “to treat” means an approach to obtain a beneficial or desirable outcome with respect to a disease, disorder, or medical condition in a subject (e.g., cancer), including, but not limited to, (a) improving a disease or medical condition, e.g., eliminating or reversing a disease or medical condition in a subject; (b) suppressing a disease or medical condition, e.g., slowing or inhibiting the progression of a disease or medical condition in a subject; or (c) reducing the symptoms of a disease or medical condition in a subject. For example, “treating cancer” would include preventing cancer recurrence, improving cancer, suppressing cancer, and reducing the symptoms of cancer. The therapeutic benefit is achieved by eliminating or improving one or more of the physiological symptoms associated with the underlying disorder so that improvement is observed in the subject, even though the subject may still be suffering from the underlying disorder.

[0054] When the term “therapeutic effect” is used herein, it encompasses the therapeutic and / or preventive benefits described above. Preventive effects include delaying or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, delaying, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0055] The terms “administer,” “give administration,” and “dosage,” and their derivatives, refer to methods that may be used to deliver a composition to a desired site of action. These methods, but are not limited to, parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular, intrathecal, intranasal, intravitreous, and local injection), transmucosal injection, oral administration, administration as a suppository, and local administration. Administration is by any route, including parenteral administration. Parenteral administrations include, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administrations. Other modes of delivery, but are not limited to, the use of liposomal formulations, intravenous infusion, and implantation. Additional methods for administering therapeutically effective doses of the compositions of this disclosure for the purpose of preventing or alleviating one or more symptoms associated with a disease are known to those skilled in the art.

[0056] The terms “effective dose,” “therapeutic effective dose,” or “therapeutic effective dosage” refer to the amount of agent sufficient to produce a beneficial or desirable outcome. The therapeutic effective dose may vary depending on one or more of the subject and disease being treated, the subject’s weight and age, the severity of the disease, and the mode of administration, which can be readily determined by those skilled in the art. An effective dose of the active agent may be administered in single or multi-dose doses. Components may be described herein as having at least an effective dose, or at least an effective dose, such as those relevant to a specific target or purpose, such as any of those described herein. The term “effective dose” also applies to doses that will provide an image for detection by appropriate imaging methods. The specific dose may vary depending on the particular agent selected, the administration regimen to be followed, whether or not it is administered concomitantly with other compounds, the timing of administration, the tissue being imaged, and one or more physical delivery systems to which the agent is carried.

[0057] The terms “sub-therapeutic dose,” “sub-effective dose,” and “sub-therapeutic dose” are interchangeable and refer to amounts less than the effective dose of the agent in question, but which, when combined with other agents in an effective or therapeutic dose or less, produce desirable results resulting from a synergistic effect in the effective effects and / or reduction of side effects obtained by the combination of, for example, (i) a sub-therapeutic dose of the agent in question and (ii) other agents (e.g., one or more different agents). For example, an agent may be approved for clinical use for a specific indication at a prescribed dose or range (e.g., 150 milligrams (mg / d) per day) during the course of one or more administrations, and a dose less than or equal to the therapeutic dose of the agent may be at least about 0.1 times, 0.2 times, 0.5 times, 1 time, 2 times, 5 times, 10 times, 20 times, 50 times, 100 times, 200 times, 500 times, 1,000 times, 2,000 times, 5,000 times, 10,000 times, 20,000 times, 50,000 times, 100,000 times, or more than the approved dose or range. A dose below the therapeutic dose of the agent may be up to approximately 100,000 times, 50,000 times, 20,000 times, 10,000 times, 5,000 times, 2,000 times, 1,000 times, 500 times, 200 times, 100 times, 50 times, 20 times, 10 times, 5 times, 2 times, 1 time, 0.5 times, 0.2 times, 0.1 times, or less than the approved dose or range. A dose below the therapeutic dose of the agent may be obtained by reducing the amount of the agent per dose and / or by reducing the number of administrations (or cycles) of the agent to the subject.

[0058] The term “synergistic effect” or “to produce a synergistic effect” refers to a situation where the desired effect (e.g., one or more different effects) of a combination of two or more different therapeutic components (e.g., two or more different treatments, two or more therapeutic agents, etc.) is greater than (i) the effect of each therapeutic component alone, and / or (ii) the sum of the effects of each therapeutic component alone when administered individually (e.g., the sum of the individual effects). The synergistic effect may be at least approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 90%, 100%, 110%, 120%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, 5,000%, or more than (i) the effect of each therapeutic component alone, and / or (ii) the sum of the individual effects. The effect may be any measurable effect, including, but is not limited to, an improvement in the therapeutic effect of the individual components in the combination, or a reduction in the side effects of the individual components in the combination. In some embodiments, the effect is a pharmacological effect, such as phosphorylated ERK (p-ERK) and / or DUSP6 inhibition, and is evaluated in whole blood at an optional rate. To obtain a synergistic effect, two or more different therapeutic components of the combination therapies disclosed herein may be administered simultaneously or sequentially, as individual components or as unit dosage forms. For example, the synergistic effect of a combination including a first agent and a second agent may result in a desirable therapeutic outcome (e.g., in cancer treatment) that is equivalent to (e.g., substantially the same) or better than (e.g., in cancer treatment) the therapeutic outcome of (i) each therapeutic component alone in an effective dose, and / or (ii) the sum of the individual effects when one or both of the first and second agents are administered at doses below their respective therapeutic doses. In another example, the synergistic effect of a combination including a first agent and a second agent may result in a desirable therapeutic outcome (e.g., reduced side effects of either one of the agents) that is equivalent to (e.g., substantially the same) or better than (e.g., reduced side effects of either agent).

[0059] The term "IC50" refers to half of the maximum inhibitory dose (e.g., concentration) of an inhibitor in inhibiting a biological or biochemical effect. IC50 can also be a quantitative measure that indicates how much of a particular inhibitor is needed to substantially inhibit (e.g., about 50%) a given biological or biochemical effect (e.g., the level of expression and / or activity of a gene / protein of interest, cell proliferation or growth rate, etc.). For example, IC50 can be determined by determining and constructing dose-response curves, examining the effects of various concentrations of an inhibitor on the reduction of cell proliferation (e.g., inhibition of cancer cell proliferation), and determining the concentration of the inhibitor at which a 50% inhibition of cell proliferation is observed.

[0060] Where applicable to agents comprising inhibitors disclosed herein, the term “combination” refers to the use of two or more agents (e.g., an SOS1 inhibitor and at least one other inhibitor that taus a different signaling molecule) in vitro, in vivo, or ex vivo. The combined two or more agents may be formulated as a single formulation or as separate formulations. Combination therapy or combination treatment using two or more agents may be performed sequentially in any chronological order and may be administered simultaneously or separately.

[0061] The term "co-administration" refers to a temporal aspect of the use of two or more agents (e.g., an SOS1 inhibitor and at least one other inhibitor against a different signaling molecule) in vitro, in vivo, or ex vivo. For example, one agent from a set of agents of interest may be administered before, after, or concurrently with the administration of a second agent in the set. Concurrent administration can be achieved by administering multiple agents simultaneously, either as separate agents or as a unit dosage form containing multiple agents.

[0062] The terms “antagonist” and “inhibitor” are used interchangeably and refer to compounds that have the ability to inhibit the biological function (e.g., activity, expression, binding, protein-protein interactions) of a target protein (e.g., SOS1). Thus, the terms “antagonist” and “inhibitor” are defined in relation to the biological role of the target protein. Preferred antagonists as used herein are compounds that specifically interact with the target (e.g., bind), but also inhibit the biological activity of the target protein by interacting with other members of the signaling pathway to which the target protein is a member, and these compounds are specifically included within this definition.

[0063] The term "selective inhibition" or "selectively inhibiting" refers to the ability of a bioactive agent to preferentially reduce target signaling activity compared to extratarget signaling activity, either through direct or indirect interaction with the target.

[0064] The terms “subject,” “individual,” and “patient” refer to animals, such as mammals, including humans. The methods described herein may be useful for both human therapeutic and veterinary applications. In some embodiments, the subject is a mammal, such as a human. “Mammals” include humans, as well as both domesticated animals, such as laboratory animals and pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), and non-domesticated animals such as wildlife. Tissues, cells, and their offspring of biological entities obtained in vivo or cultured in vitro are also included.

[0065] The terms "therapeutic agent," "therapeutic drug," or "treatment agent" are used interchangeably and refer to molecules or compounds that, when administered to a subject, produce some beneficial effect. Beneficial effects include enabling diagnostic determination, improving a disease, symptom, disorder, or pathological condition, reducing or preventing the onset of a disease, symptom, disorder, or condition, and substantially counteracting a disease, symptom, disorder, or pathological condition.

[0066] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. Polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass any other operations on modified amino acid polymers, such as the formation of disulfide bonds, glycosylation, lipidation, acetylation, phosphorylation, or binding with labeling components. As used herein, the term “amino acid” refers to any amino acid, whether natural and / or unnatural or synthetic, including glycine and both D or L optical isomers, as well as amino acid analogs and peptide mimetic compounds.

[0067] The terms "polynucleotide," "nucleotide," "nucleotide sequence," "nucleic acid," and "oligonucleotide" are used interchangeably. These refer to polymeric forms of nucleotides of any length, which are either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. Non-limiting examples of polynucleotides include: coding or non-coding regions of genes or gene fragments, loci (groups of loci) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The polynucleotide may contain one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs, e.g., peptide nucleic acids (PNA), morpholino and locked nucleic acids (LNA), glycol nucleic acids (GNA), threose nucleic acids (TNA), 2'-fluoro, 2'-OMe, and phosphorothiolated DNA. If present, modifications to the nucleotide structure may be made before or after polymer construction. The nucleotide sequence may be interrupted by non-nucleotide components. The polynucleotide may be further modified after polymerization, such as by binding to labeling components or other binding targets.

[0068] The term "nucleic acid agent" refers to an inhibitor that can downregulate (e.g., reduce or inhibit) the expression and / or activity of a target region (e.g., a protein or the gene encoding it). In some embodiments, the nucleic acid agent may consist of a nucleic acid molecule. In some embodiments, the nucleic acid agent may include a nucleic acid molecule. In some embodiments, the nucleic acid agent may include both a nucleic acid molecule and a non-nucleic acid molecule. The nucleic acid molecule and the non-nucleic acid molecule may be operably bound to each other to produce an inhibitory effect on the target region. The nucleic acid molecule and the non-nucleic acid molecule may be bound to each other (e.g., covalently and / or non-covalently). In some cases, the nucleic acid molecule and the non-nucleic acid molecule may be linked to each other via a linker. In some cases, the nucleic acid molecule may be configured to bind to a non-nucleic acid molecule. In some cases, the non-nucleic acid molecule may be configured to bind to a nucleic acid molecule. Non-limiting examples of non-nucleic acid molecules include small molecules, polypeptides (e.g., enzymes), etc. In some cases, the non-nucleic acid molecule is a nuclease, e.g., an endonuclease.

[0069] In this specification, “expression” refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcripts), and / or the process by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. The transcripts and encoded polypeptides may be collectively referred to as “gene products.” If the polynucleotide is derived from genomic DNA, expression may include the splicing of mRNA in eukaryotic cells.

[0070] An "antigen" is a portion or molecule containing an epitope that also specifically binds to an antibody. An "antigen-binding unit" can be the whole or a fragment (or group of fragments) of a full-length antibody, its structural variant, its functional variant, or a combination thereof. Full-length antibodies can be, for example, monoclonal antibodies, recombinant antibodies, chimeric antibodies, deimmunized antibodies, humanized antibodies, and human antibodies. Examples of full-length antibody fragments include variable heavy chains (VH), variable light chains (VL), and heavy chains (VHH or VL) found in camelids such as camels, llamas, and alpacas. H H) Examples include, but are not limited to, single-domain antibodies (sdAb, e.g., "nanobody") containing heavy chains (V-NAR domains) found in sharks, a single antigen-binding domain, Fv, Fd, Fab, Fab', F(ab')2, and "r IgG" (or semi-antibodies). Examples of modified antibody fragments include, but are not limited to, scFv, di-scFv, or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single-chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, minibodies (e.g., (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3), or (scFv-CH3-scFv)2), and multibodies (e.g., triabodies or tetrabodies).

[0071] The terms “antibody” and “antibody group” include any antigen-binding unit, including but not limited to monoclonal antibodies, human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, and other epitope-binding fragments.

[0072] The term "disease cells" refers to a state of cells, tissues, or organisms that deviates from a normal or healthy state. Disease cells may result from the effects of pathogens, toxic substances, radiation, or intracellular dysregulation (e.g., gene mutations). In some cases, disease cells are cells infected with a pathogenic virus. In other cases, disease cells are malignant or neoplastic cells that can constitute or cause cancer in a subject (e.g., a mammal such as a human subject).

[0073] The term "prodrug" refers to a compound that, under physiological conditions, can be converted by solvolysis to a biologically active compound described herein (e.g., the compound of formula (I)). Therefore, the term "prodrug" refers to a precursor of a pharmaceutically acceptable biologically active compound. A prodrug is inactive when administered to a subject but is converted in vivo to an active compound, for example, by hydrolysis. Prodrug compounds often offer advantages in mammalian organisms, such as solubility, histocompatibility, or delayed release (see, for example, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam), Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” (1987) ACSSymposium Series, Vol. 14, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, each of which is fully incorporated herein by reference). The term “prodrug” also means any covalent carrier that releases the active compound in vivo when such a prodrug is administered to a mammalian subject. Prodrugs of active compounds described herein are typically prepared by modifying a functional group present in the active compound such that the modification is cleaved into the parent active compound, either in a routine operation or in vivo. Examples of prodrugs include compounds in which a hydroxyl group, an amino group, or a mercapto group is cleaved when the prodrug of the active compound is administered to a mammalian subject to form a free hydroxyl group, a free amino group, or a free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetic acid, formic acid, and benzoic acid derivatives of the hydroxyl functional group in the active compound, or acetamide, formamide, and benzamide derivatives of the amine functional group.

[0074] The term "in vivo" refers to events that occur within the body of the subject. The term "ex vivo" refers to events that initially occur outside the body of the subject in order to later apply them in vivo within the body of the subject. For example, ex vivo preparation may include preparing cells outside the body of the subject for the purpose of introducing the prepared cells into the body of the same or different subject. The term "in vitro" refers to events that occur outside the body of the subject. For example, an in vitro assay encompasses any assay performed outside the body of the subject. In vitro assays include cell-based assays in which living or dead cells are used. In vitro assays also include cell-free assays that do not use intact cells.

[0075] This disclosure also means that it encompasses in vivo metabolites of the disclosed compounds. Such products may arise, for example, from oxidation, reduction, hydrolysis, amidation, esterification, etc., of the administered compound, primarily due to enzymatic processes. Thus, this disclosure includes compounds produced by processes that involve administering the compounds disclosed herein to mammals for a period of time sufficient to obtain their metabolites. Such products are typically identified by administering the radiolabeled compounds of this disclosure to animals such as rats, mice, guinea pigs, monkeys, or humans in a detectable dose, allowing sufficient time for metabolism to occur, and then isolating the converted products from urine, blood, or other biological samples.

[0076] The term "Ras" or "RAS" refers to proteins of the rat sarcoma (Ras) superfamily of low molecular weight GTPases, such as the Ras subfamily. The Ras superfamily includes, but is not limited to, the Ras subfamily, Rho subfamily, Rab subfamily, Rap subfamily, Arf subfamily, Ran subfamily, Rheb subfamily, RGK subfamily, Rit subfamily, Miro subfamily, and unclassified subfamily. In some embodiments, the Ras protein is selected from the group consisting of KRAS (K-Ras, K-ras, or Kras), HRAS (or H-Ras), NRAS (or N-Ras), MRAS (or M-Ras), ERAS (or E-Ras), RRAS2 (or R-Ras2), RALA (or RalA), RALB (or RalB), RIT1, and any combination thereof, for example, selected from KRAS, HRAS, NRAS, RALA, RALB, and any combination thereof.

[0077] "Osimertinib" refers to a kinase inhibitor for oral use. The molecular formula for osimertinib mesylate is C 28 H 33 It is N7O2-CH4O3S and has a molecular weight of 596 g / mol. The chemical name of osimertinib mesylate is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindole-3-yl)pyrimidine-2-yl]amino}phenyl)propa-2-enamide mesylate. Osimertinib has the following structural formula (as osimertinib mesylate): [ka] Osimertinib, marketed under the brand name Tagrisso, has the following indications: (a) adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) in whom FDA-approved testing has revealed epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation in the tumor; (b) first-line treatment in adult patients with metastatic NSCLC in whom FDA-approved testing has revealed EGFR exon 19 deletion or exon 21 L858R mutation in the tumor; (c) first-line treatment in combination with pemetrexed and platinum-based chemotherapy in adult patients with locally advanced or metastatic NSCLC in whom FDA-approved testing has revealed EGFR exon 19 deletion or exon 21 L858R mutation in the tumor; and (d) treatment in adult patients with metastatic NSCLC in whom FDA-approved testing has revealed EGFR T790M mutation positivity and whose disease has progressed during or after EGFR TKI therapy. Tagrisso tablets contain 40 or 80 mg of osimertinib, corresponding to 47.7 and 95.4 mg of osimertinib mesylate, respectively. The inactive components in the tablet core are mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. The tablet coating consists of polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, yellow iron oxide, red iron oxide, and black iron oxide. References to osimertinib herein include osimertinib and its pharmaceutically acceptable salts (including osimertinib mesylate).

[0078] method The SOS1 inhibitors and their pharmaceutical compositions disclosed herein are particularly useful for the treatment of epidermal growth factor receptor (EGFR)-mediated diseases and associated symptoms. Common EGFR mutations, including variable deletions of at least three amino acid residues in exon 19 (exon 19 deletions), L858R point mutations in exon 21, and exon 20 insertion mutations (ex20ins), are activating mutations that result in constitutive activation of EGFR and downstream signaling pathways, particularly in non-small cell lung cancer (NSCLC). Cancers harboring exon 19 deletions and L858R mutations are typically more sensitive to EGFR inhibitors such as gefitinib and erlotinib compared to cancers in which no EGFR mutations are detected. However, exon 20 insertions result in constitutive activation of EGFR, are associated with resistance to EGFR inhibitors, and correlate with poor patient prognosis. Osimertinib, a third-generation irreversible EGFR inhibitor, is approved for adjuvant therapy and treatment in metastatic cases of patients with EGFR-activating mutations (exon 19 deletion and exon 21 L858R), as well as for treatment of exon 20 T790M mutations. However, treated patients often eventually develop resistance to osimertinib, resulting in cancer recurrence. Furthermore, osimertinib monotherapy may have limited efficacy in exon 20-mutated NSCLC at a standard dose of 80 mg, and there is evidence suggesting that higher doses (e.g., 160 mg of osimertinib) may be required to demonstrate clinical benefit. The compositions and methods disclosed herein open new avenues for overcoming osimertinib drug resistance to EGFR-mediated cancers and offer the potential for first-line treatment with sustained and long-term efficacy. In some embodiments, the compositions and methods described herein are particularly useful for the treatment of NSCLC in which exon 19 deletions, L858R mutations, T790M mutations, C797S mutations, and / or exon 20 insertions are detected. The combination of osimertinib and SOS1 inhibitors described herein may overcome resistance and provide synergistic benefits in the treatment of EGFR-mutated NSCLC.

[0079] In one embodiment, the present disclosure provides a method for reducing the proliferation of cancer cells containing an epidermal growth factor receptor (EGFR) exon 20 insertion, which is administered to cells by (a) an SOS1 inhibitor and (b) osimertinib, wherein (a) is administered before, simultaneously with, or after the administration of (b). In some embodiments, the cancer cells are non-small cell lung cancer cells.

[0080] In one embodiment, the disclosure provides a method for downregulating EGFR signaling output in a plurality of non-small cell lung cancer cells, comprising (i) evaluating the EGFR mutation status in a biological sample containing nucleic acids from a subject, and (ii) administering, if an EGFR exon 20 insertion is detected in the sample, (a) being administered before, simultaneously with, or after the administration of (b).

[0081] In another embodiment, the Disclosure provides a method of adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) in which FDA-approved testing reveals an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation in the tumor, the method comprising administering (a) an SOS1 inhibitor and (b) osimertinib. In a particular embodiment, the Disclosure provides a method of first-line treatment in adult patients with metastatic NSCLC in which FDA-approved testing reveals an EGFR exon 19 deletion or exon 21 L858R mutation in the tumor, the method comprising administering (a) an SOS1 inhibitor and (b) osimertinib. In certain embodiments, the Disclosure provides a method for treating adult patients with metastatic NSCLC who have been determined to be positive for the EGFR T790M mutation by FDA-approved testing and whose disease has progressed during or after EGFR TKI therapy, the method comprising administering (a) an SOS1 inhibitor and (b) osimertinib. In certain embodiments, the Disclosure provides a method for treating adult patients with locally advanced or metastatic NSCLC in which the tumor has been found to have an EGFR exon 19 deletion or exon 21 L858R mutation by FDA-approved testing, the method comprising administering (a) an SOS1 inhibitor, (b) osimertinib, (c) pemetrexed, and (d) platinum-based chemotherapy.

[0082] In yet another aspect, the disclosure provides a method for treating or improving the symptoms of an EGFR-mediated disease or condition in a subject that requires it. The method may include administering (a) an SOS1 inhibitor and (b) osimertinib to the subject.

[0083] In yet another embodiment, this specification provides a method for treating EGFR-mediated cancer in a subject. The method comprises administering (a) an SOS1 inhibitor and (b) osimertinib to the subject, wherein (a) is administered before, concurrently with, or after the administration of (b), and the administrations of (a) and (b) synergistically reduce the proliferation of cancer cells with a synergistic effect value of at least 0.1, as confirmed by the Bliss independence criterion.

[0084] In another aspect, the disclosure provides a method for treating EGFR-mutated NSCLC that has progressed during osimertinib treatment in a subject, the method comprising (a) administering an SOS1 inhibitor and (b) osimertinib to the subject. EGFR-mutated NSCLC may have progressed during osimertinib treatment in a locally advanced or metastatic setting, or relapsed in an adjuvant therapy setting.

[0085] Any method described herein, comprising (a) administering an SOS1 inhibitor and (b) osimertinib, may further comprise (c) administering an additional agent or additional therapy. Suitable agents that may be administered in combination with (a) an SOS1 inhibitor and (b) osimertinib include other anticancer agents, anti-allergic agents, anti-nausea (or antiemetic) agents, analgesics, cytoprotective agents, immunomodulators, steroids, chemotherapeutic agents, and combinations thereof. In some embodiments, the additional therapy is selected from surgery, cell therapy, chemotherapy, and radiation. In some embodiments, the method described herein comprises administering (a) an SOS1 inhibitor, (b) osimertinib, (c) pemetrexed, and (d) platinum-based chemotherapy. In some embodiments, the method described herein comprises administering (a) an SOS1 inhibitor, (b) osimertinib, and (c) pemetrexed. In some embodiments, the methods described herein include administering (a) an SOS1 inhibitor, (b) osimertinib, and (c) platinum-based chemotherapy.

[0086] In yet another embodiment, a method is provided for treating EGFR-mediated cancer in a subject, the method comprising administering to the subject a pharmaceutical composition comprising (i) a SOS1 inhibitor of formula (I-1) or a pharmaceutically acceptable salt or solvate thereof, (ii) osimertinib, and (iii) a pharmaceutically acceptable excipient.

[0087] When performing one or more of the methods disclosed herein, the disease or condition may be a cancer containing an EGFR mutation, including but not limited to an exon 19 deletion, L858R mutation, T790M mutation, C797S mutation, and / or an exon 20 insertion. In some embodiments, the cancer contains an exon 20 insertion. In some embodiments, the cancer contains a G719x mutation, S768I mutation, and / or L861Q mutation. When performing one or more of the methods disclosed herein, the disease or condition may be NSCLC containing an EGFR mutation, including but not limited to an exon 19 deletion, L858R mutation, T790M mutation, C797S mutation, G719x mutation, S768I mutation, L861Q mutation, and / or an exon 20 insertion.

[0088] EGFR-mediated diseases or conditions can be any disease or condition in which the EGFR signaling pathway contributes to the progression of the disease or condition. In some embodiments, the disease or condition is characterized by abnormal activation of EGFR, resulting in optional EGFR amplification, EGFR overexpression, overexpression of an EGFR ligand, and / or the occurrence of one or more EGFR mutations. EGFR-mediated diseases or conditions include, but are not limited to, cancers (e.g., lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, anal cancer, ovarian cancer, breast cancer, colorectal cancer, bladder cancer, esophageal cancer, glioblastoma, and head and neck cancers), inflammatory diseases (e.g., psoriasis, eczema, atopic dermatitis, and atherosclerosis), and kidney diseases (e.g., renal fibrosis, chronic kidney disease, acute kidney injury, obstructive nephropathy, diabetic nephropathy, hypertensive nephropathy, and glomerulonephritis). In some embodiments, the EGFR-mediated disease or condition is an EGFR-mediated cancer. In some embodiments, the cancer is a lung cancer, such as non-small cell lung cancer (NSCLC). In some embodiments, the NSCLC is locally advanced or metastatic NSCLC. In some embodiments, the lung cancer is not primarily squamous type NSCLC and / or small cell lung cancer. In some embodiments, the cancer is metastatic, such as metastatic NSCLC. In some embodiments, the cancer contains EGFR mutations, such as mutations selected from L858R, T790M, C797S, G719x, S768I, L861Q, exon 19 deletions, and exon 20 insertions. In some embodiments, the cancer contains EGFR mutations, such as mutations selected from L858R, T790M, C797S, exon 19 deletions, and exon 20 insertions. In some embodiments, the cancer contains exon 20 insertions. In some embodiments, the cancer includes double or triple EGFR variants such as T790M / C797S, L858R / T790M, del19 / T790M / C797S, or L858R / T790M / C797S. In some embodiments, the cancer includes abnormal MET expression, such as MET overexpression or MET amplification.

[0089] Determining whether a tumor or cancer contains an EGFR mutation can be done by evaluating the nucleotide sequence encoding the protein, by evaluating the amino acid sequence of the protein, or by evaluating the characteristics of the putative protein. Exemplary nucleic acid assays, but not limited to, include genotyping assays and sequencing methods. Sequencing methods include next-generation sequencing, targeted sequencing, exome sequencing, whole-genome sequencing, and massively parallel sequencing. Several platforms for next-generation sequencing are commercially available, including instruments sold by Illumina and Pacific Biosciences. Additional nucleic acid assays, but not limited to, include in situ hybridization (e.g., FISH), polymerase chain reaction (PCR), quantitative PCR (qPCR), quantitative real-time PCR (qRT-PCR), and ligase chain reaction (LCR), all of which are applicable to the detection of genetic abnormalities in EGFR. If necessary, one or more nucleic acids can be used to detect genetic abnormalities that result in the formation of the EGFR gene, including translation, as well as to detect gene mutations within the EGFR gene by point mutations, insertions, deletions, or frameshifts.

[0090] Additional methods for detecting the nucleotide sequence of a gene include, but are not limited to, polymerase chain reaction restriction enzyme fragment length polymorphism (PCR-RFLP) assays, polymerase chain reaction single-strand structure polymorphism (PCR-SSCP) assays, real-time PCR assays, PCR sequencing, mutant allele-specific PCR amplification (MASA) assays, direct sequencing, primer extension reactions, electrophoresis, oligonucleotide ligation assays, hybridization assays, TaqMan assays, SNP genotyping assays, high-resolution thawing assays, and microarray analysis. In some embodiments, EGFR mutations are identified using direct sequencing of specific regions within the gene. This technique can identify all possible mutations in the sequenced region. Methods for detecting mutant EGFR proteins include, but are not limited to, detection of mutant proteins using mutant protein-specific binders (e.g., antibodies), protein electrophoresis and Western blotting, and direct peptide sequencing. In some embodiments, EGFR mutations are identified using PCR-based or next-generation sequencing (NGS)-based diagnostic methods. In some embodiments, EGFR mutations are identified using PCR-based diagnostic methods. In some embodiments, EGFR mutations are identified using NGS-based diagnostic methods.

[0091] In some embodiments, the presence of EGFR mutations such as exon 19 deletion, exon 21 L858R substitution mutation, and / or T790M is determined in tumor or plasma samples using FDA-approved tests such as cobas EGFR Mutation Test v1 (Roche Molecular Systems, Inc.), cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.), FoundationOne CDx (Foundation Medicine, Inc.), FoundationOne Liquid CDx (Foundation Medicine, Inc.), Guardant360 CDx (Guardant Health, Inc.), ONCO / Reveal Dx Lung & Colon Cancer Assay (O / RDx-LCCA, Pillar Biosciences, Inc.), Oncomine Dx Target Test (Life Technologies Corporation), or therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.). In some embodiments, the presence of EGFR mutations such as L861Q, G719X, and / or S7681 is determined in tumor or plasma samples using FDA-approved tests such as therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.). In some embodiments, EGFR protein expression is assessed in tumor or plasma samples using FDA-approved tests such as the Dako EGFR pharmDx Kit (Dako North America, Inc.). In some embodiments, the presence of EGFR mutations such as exon 20 insertion mutations is determined in tumor or plasma samples using FDA-approved tests such as FoundationOne Liquid CDx (Foundation Medicine, Inc.), Guardant360 CDx (Guardant Health, Inc.), or Oncomine Dx Target Test (Life Technologies Corporation).

[0092] Methods for determining whether a disease or condition is mediated by or dependent on polypeptides such as EGFR or MET are known to those skilled in the art. These methods include, but are not limited to, cell proliferation assays, transcriptome assays such as RNA-seq or hybridization assays, and protein detection assays such as immunoassays. In some embodiments, EGFR-mediated diseases or conditions are diseases or conditions involving known EGFR-activating mutations such as exon 19 deletion, L858R, T790M, or exon 20 insertion. Various techniques for protein analysis are also applicable to assessing the presence and / or overexpression of EGFR or its variants, as well as the expression of other proteins associated with EGFR TKI resistance. Suitable protein assays include, but are not limited to, immunohistochemistry (IHC), ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometry assays, in situ immunoassays, Western blot analysis, immunoprecipitation assays, immunofluorescence assays, flow cytometry, confocal microscopy, enzyme assays, surface plasmon resonance, and PAGE-SDS. One or more of these protein assays utilize antibodies or fragments that exhibit specific binding to EGFR polypeptides. Numerous anti-EGFR antibodies are available, including those offered by Thermofisher and Abcam. Commercially available antibodies can also be used in immunoassays to confirm decreased EGFR TKI binding affinity to BCR-ABL as a result of genetic mutations in the EGFR gene.

[0093] A variety of samples can be used for determining whether a tumor or cancer contains an EGFR mutation. In some embodiments, the sample is taken from a subject having a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed, paraffin-embedded sample. In some embodiments, the sample is treated with a cell lysate. In some embodiments, the sample is treated with DNA or RNA. In some embodiments, the sample is a plasma sample. In some embodiments, the sample contains cell-free DNA (cfDNA). In some embodiments, the method utilizes circulating cfDNA derived from peripheral whole blood plasma taken from a subject.

[0094] In carrying out the methods of this disclosure, the presence of the EGFR gene, mutations within the EGFR gene, or other genetic abnormalities associated with resistance to EGFR TKIs can be determined using any biological sample containing target cells (e.g., cancer cells from the subject under investigation) or components thereof (e.g., components such as cfDNA derived from tumor tissue or cancer cells). The biological sample may be a liquid or solid biological sample derived from the subject under investigation or treatment. The biological sample may be a fixed, paraffin-embedded, fresh, or frozen biopsy sample. The biological sample may be obtained by any suitable means, including, but not limited to, blood collection, needle aspiration, microneedle aspiration, core needle biopsy, vacuum-assisted biopsy, large core biopsy, incision biopsy, excision biopsy, punch biopsy, thin section biopsy, skin biopsy, surgical specimen, and venous puncture.

[0095] Depending on the tumor tissue or cancer cells being treated, the biological sample may be obtained from, but is not limited to, blood or plasma, skin, heart, lungs, kidneys, bone marrow, breast, pancreas, liver, muscle, smooth muscle, bladder, gallbladder, colon, intestines, brain, prostate, esophagus, thyroid, serum, saliva, urine, gastric juice and digestive fluids, tears, feces, semen, vaginal fluid, interstitial fluid derived from tumor tissue, eye fluid, sweat, mucus, earwax, oil, glandular secretions, cerebrospinal fluid, hair, nails, plasma, nasal swab or nasopharyngeal lavage fluid, cerebrospinal fluid, cerebrospinal fluid, tissue, pharyngeal swab, biopsy, placental fluid, amniotic fluid, umbilical cord blood, concentrated fluid, body cavity fluid, saliva, pus, microbiome, meconium, milk, and / or other excretions or body tissues of the subject.

[0096] In some embodiments, the biological sample comprises cell-free DNA (cfDNA) derived from the whole blood or plasma of the subject. The sample may be analyzed directly for its contents, or it may be processed to purify one or more of its contents before analysis. In some embodiments, the components of the biological sample to be purified are proteins (e.g., total protein, cytoplasmic protein, or membrane protein). In some embodiments, the components of the sample to be purified are nucleic acids such as DNA (e.g., genomic DNA, cDNA, ctDNA, or cfDNA) or RNA (e.g., total RNA, mRNA, or microRNA).

[0097] EGFR exon 20 insertions include in-frame insertions within exon 20 of EGFR. In some embodiments, EGFR exon 20 insertions are found between residues E762 and C775. In some embodiments, EGFR exon 20 insertions are found after E762, A763, Y764, V765, M766, A767, S768, V769, D770, N771, P772, H773, V774, or C775. In some embodiments, EGFR exon 20 insertions are found after residues L747, A763, Y764, M766, A767, V769, D770, P772, or H773. In some embodiments, EGFR exon 20 insertions are found after residues V769 or D770. In some embodiments, the EGFR exon 20 insertion is selected from A763_Y764ins, Y764_V765ins, M766_A767ins, A767_V769dup, V769_D770ins, D770_N771ins, delD770ins, P772_H773ins, P772_V774ins, and H773_V774ins. In some embodiments, the EGFR exon 20 insertion is selected from D770_N771ins and V769_D770ins. In some embodiments, the EGFR exon 20 insertion is selected from delL747_P753insS, A763_Y764insFQEA, Y764_V765insHH, M766_A767insAI, M766_A767insASV, A767_V769dupASV, V769_D770insASV, D770_N771insGL, D770_N771insGT, D770_N771insNPG, D770_N771insSVD, delD770insGY, P772_H773insYNP, P772_V774insPHV, H773_V774insH, and H773_V774insNPH. In some embodiments, the EGFR exon 20 insertion is selected from D770_N771insSVD and V769_D770insASV. In some embodiments, the EGFR exon 20 insertion consists of 1 to 4 amino acid residues, such as 1, 2, 3, or 4 amino acid residues.In some embodiments, cancers involving EGFR exon 20 insertions are insensitive to treatment with gefitinib or erlotinib.

[0098] When administering one or more combination therapies disclosed herein, the synergistic effect of a given combination may be characterized by a synergistic value calculated by the “Bliss independence-beyond effect” or “BLISS” independence criterion. The Bliss independence criterion can be used to screen candidate drug combinations. This criterion allows for the comparison of observed combination responses with predicted combination responses. Predicted combination responses are obtained based on the assumption that there are no effects from drug interactions. A combination effect can be determined to be synergistic when the observed combination response is greater than the predicted combination response (e.g., greater than a threshold). To determine the synergistic value of a combination therapy involving inhibitor (a) (e.g., an SOS1 inhibitor) and inhibitor (b) (e.g., osimertinib or a MET inhibitor) with respect to the induction of inhibition of target cell proliferation (e.g., NSCLC cells), the BLISS independence criterion can utilize the following formula: Y AB,O -Y AB,P (1) During the ceremony, Y AB,O This is the percentage of target cell proliferation inhibition observed by a combination including dose A(a) and dose B(b), Y AB,P This is the predicted percentage of target cell proliferation inhibition by a combination including dose A(a) and dose B(b), where, Y AB,P= Y A +Y B -Y A Y B (2) Furthermore, during the ceremony, Y A This is the percentage of target cell proliferation inhibition observed by dose A(a) alone. Y B This is the percentage of target cell proliferation inhibition observed by dose B(b) alone. Y AY B Y A and Y B It is the product of the two. Y is the percentage of inhibition for the observed combination. AB,O Y is the predicted growth inhibition rate according to equation (1). AB,P This is compared with the following. By making this comparison, it is possible to determine whether the combination therapy promotes a synergistic effect, an additive effect, or an antagonistic effect, as summarized in equation (3). AB,O >Y AB,P In this case, combination therapy can be determined to be more effective than expected (e.g., synergistic effect). AB,O <Y AB,P In this case, the combination therapy can be determined to be worse than expected (e.g., antagonistic effect). AB,O =Y AB,P In this case, combination therapy can be determined to be substantially the same as simply adding two separate drugs together (e.g., independent effects or additive effects).

number

[0099] When using the Bliss independence criterion, the percentage of target cell proliferation inhibition can be provided on a percentage scale (e.g., approximately 0% to approximately 100%) or a fractional scale (e.g., approximately 0 to 1). For the purpose of analysis according to the Bliss independence criterion, for example, 75% inhibition of target cell proliferation can be expressed as 0.75. For example, when a fractional scale is used, the observed combination of inhibition percentages Y (e.g., based on one or more in vitro experiments) can be expressed as Y. AB,O And, according to equation (1), the predicted growth inhibition rate Y AB,PThe difference between two factors can be determined to be additive (or antagonistic) if the difference is zero or less. Such a difference can be determined to be synergistic if the difference is greater than zero. Here, a synergistic effect can be divided into several subranges, for example, a first synergistic subrange with a difference of about 0.05 to about 0.1 (e.g., mild synergy), a second synergistic subrange with a difference of about 0.1 to about 0.2 (e.g., moderate synergy), and a third synergistic subrange with a difference of 0.2 or more (e.g., stable synergy).

[0100] In some embodiments, combination therapies comprising multiple agents (e.g., an SOS1 inhibitor and osimertinib disclosed or exemplified herein, or an SOS1 inhibitor and a MET inhibitor disclosed or exemplified herein) can be used to reduce the growth or proliferation of target cells, such as NSCLC cells, in vitro or in vivo. The therapeutic efficacy of combination therapies can be characterized by a synergistic value greater than 0.1 when confirmed by the Bliss independence criterion. The therapeutic efficacy of combination therapies can be characterized by a synergistic value of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, or higher when confirmed by the Bliss independence criterion. The therapeutic efficacy of combination therapy can be characterized by synergistic values ​​of approximately 0.1 to 1, approximately 1.0 to 5, approximately 5 to 10, or approximately 10 to 15. In some embodiments, the synergistic value is at least 0.4, such as at least 1. In some embodiments, the synergistic value is at least 5.

[0101] In some embodiments, the subjects are naive subjects who have not been treated for cancer. In some embodiments, the naive subjects have not been treated with a TKI against EGFR prior to administration of (a) and (b). In some embodiments, the subjects are being treated with chemotherapy. In some embodiments, the subjects have undergone surgery to treat cancer. In some embodiments, the subjects have not been treated with chemotherapy. In some embodiments, the subjects have undergone surgery. In some embodiments, the subjects have been treated with a non-osimertinib TKI against EGFR prior to administration of (a) and (b). In some embodiments, the subjects have not been treated with osimertinib as a TKI prior to administration of (a) and (b).

[0102] In some embodiments, subjects suitable for the therapeutic methods of the present disclosure have been previously treated with one or more tyrosine kinase inhibitors (TKIs) against EGFR prior to administration of (a) and (b). In some embodiments, subjects have been previously treated with a first-generation EGFR TKI (e.g., gefitinib), a second-generation EGFR TKI (e.g., afatinib), or a third-generation EGFR TKI (e.g., osimertinib). In some embodiments, subjects have been previously treated with a non-exon 20 insertion EGFR TKI such as gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, BLU-945, or zolifertinib. In some embodiments, the subject has been previously treated with gefitinib, erlotinib, or afatinib. In some embodiments, the subject has been previously treated with osimertinib. In some embodiments, the cancer has progressed during osimertinib treatment. In some embodiments, the subject has EGFR-mutated NSCLC that has progressed during osimertinib treatment. In some embodiments, the EGFR-mutated NSCLC has progressed during osimertinib treatment in a locally advanced or metastatic setting, or has recurred in an adjuvant therapy setting. In some embodiments, the subject has been previously treated with an EGFR exon 20 insertion TKI such as poziotinib, mobocertinib, amivantamab, diparereltinib, sambozertinib, BAY-2927088, BLU-451, or STX-721. In some embodiments, the subject has been previously treated with amivantamab. In some embodiments, the subject has been previously treated with an EGFR TKI selected from gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, BLU-945, zolifertinib, poziotinib, mobocertinib, amibantamab, diparereltinib, sambozertinib, BAY-2927088, BLU-451, and STX-721.In some embodiments, subjects suitable for the therapeutic methods of the Disclosure have been previously treated with platinum-based chemotherapy before administering (a) and (b). In some embodiments, the disease of the subject has progressed during or after platinum-based chemotherapy. In some embodiments, the subject has undergone tumor resection.

[0103] While significant progress has been made with the emergence of several generations of EGFR TKIs, drug resistance and / or intolerance to earlier generations of TKIs severely limits treatment options for patients who exhibit resistance or intolerance to one or more EGFR TKIs, or who have relapsed after treatment with one or more EGFR TKIs. EGFR TKI resistance may be characterized by one or more changes selected from (1) cancer progression, (2) EGFR gene mutations including point mutations, insertions, deletions, and translocations, (3) loss of the EGFR T790M mutation, (4) EGFR gene amplification, (5) MET amplification, (6) HER2 amplification, (7) RAS-MAPK pathway activation, (8) PI3K pathway activation, (9) cell cycle gene changes, (10) oncogenic fusion, (11) histological transformation, and (12) phenotypic transformation. In some embodiments, EGFR TKI resistance is characterized by exon 20 insertions resulting in reduced TKI binding affinity to EGFR. In some embodiments, EGFR TKI-resistant subjects include one or more mutations selected from L858R, T790M, C797S, exon 19 deletion, and exon 20 insertion. In some embodiments, EGFR TKI-resistant subjects include, but are not limited to, double or triple EGFR variants, including T790M / C797S, L858R / T790M, del19 / T790M / C797S, and L858R / T790M / C797S.

[0104] In some embodiments, subjects suitable for the therapeutic methods of the present disclosure exhibit intolerance to EGFR TKIs. Osimertinib has many known side effects, including diarrhea, rash, nausea, decreased appetite, thrombocytopenia, leukopenia, epistaxis, alopecia, hand-foot syndrome, increased creatinine, increased creatinine phosphokinase, stomatitis, vomiting, paronychia, fatigue, dry skin, loss of appetite, headache, anemia, pneumonia, pruritus, constipation, and / or cough, any or all of which may cause subjects to be intolerant to EGFR TKI treatment.

[0105] Patients resistant to EGFR TKI treatment may show progression of disease or condition, such as cancer (e.g., NSCLC), despite treatment with EGFR TKIs. An exemplary EGFR-mediated cancer is NSCLC, which typically presents with one or more symptoms, including cough, hemoptysis, chest pain or discomfort, shortness of breath, wheezing, hoarseness, loss of appetite, unexplained weight loss, fatigue, dysphagia, and swelling of the facial and / or jugular veins. Progression of NSCLC may be observed using one or more imaging techniques, such as CT, PET, or MRI scans, or bronchoscopy.

[0106] Progression may be established by the absence of reduction in any or some of the symptoms disclosed herein, or any of the symptoms known in the art that are associated with EGFR-mediated cancers, such as NSCLC. In some embodiments, progression is established, for example, by the absence of reduction in one or more symptoms three, four, five, six, seven, eight, nine, ten, eleven, or twelve months or more after initial treatment with an EGFR TKI.

[0107] In some embodiments, subjects suitable for the therapeutic methods of the Disclosure have a recurrence of an EGFR-mediated cancer, such as lung cancer. In some embodiments, subjects have a recurrence of NSCLC. Recurrence may be established by the recurrence of any of the symptoms associated with the cancer previously diagnosed in the subject, or by detection of cancer via appropriate methods such as CT scan, PET scan, MRI, bronchoscopy, or lung biopsy. Recurrence may occur, for example, 3, 5, 7, 8, 9, 10, 11, 12, 15, 18, 24, 25, 26, 27, 28, 29, 30, 36 months or more after initial treatment with an EGFR TKI.

[0108] In carrying out the methods disclosed herein, administering an SOS1 inhibitor, or a pharmaceutical composition containing an effective amount of an SOS1 inhibitor, typically involves contacting cells with the SOS1 inhibitor disclosed herein. The SOS1 inhibitor may be a small molecule, a nucleic acid agent, or a polypeptide (e.g., an endonuclease). As disclosed herein, the contact may be carried out in vitro, ex vivo, or in vivo.

[0109] In some embodiments, cells are contacted with (i) an SOS1 inhibitor disclosed herein, and (ii) osimertinib and / or a MET inhibitor. Contact with (i) and (ii) may be carried out sequentially. For example, the SOS1 inhibitor may be administered before, after, or concurrently with the administration of osimertinib or a MET inhibitor. For concurrent contact, the target SOS1 inhibitor and osimertinib, or the target SOS1 inhibitor and a MET inhibitor, or the target SOS1 inhibitor, osimertinib, and a MET inhibitor may be present in the same composition (e.g., as a formulation or unit dose form) or in different compositions (e.g., cells are simultaneously exposed to two or three different compositions). For sequential contact, the target SOS1 inhibitor and osimertinib, the target SOS1 inhibitor, osimertinib, and a MET inhibitor, or the target SOS1 inhibitor and a MET inhibitor may be present in the same composition (e.g., a single composition exhibiting different release profiles, or different compositions). For continuous contact, the first contact with cells (e.g., contact with an SOS1 inhibitor, osimertinib, or MET inhibitor) and the second contact with cells (e.g., contact with a MET inhibitor, osimertinib, or SOS1 inhibitor) may be divided into intervals of, for example, at least about 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 24 hours, 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or longer. The first and second contacts may be divided into intervals of up to about 1 month, 1 week, 24 hours, 20 hours, 16 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 60 minutes, or less. When carrying out any of the methods of this disclosure, (a) and (b) may be administered in the same formulation. In some embodiments, (a) and (b) are administered in separate formulations.

[0110] In certain embodiments, the Disclosure provides a method for treating a MET-mediated cancer, such as NSCLC, in a subject, the method comprising administering an SOS1 inhibitor to the subject. The method may further comprise administering (b) a MET inhibitor. In certain embodiments, the Disclosure provides a method for treating a cancer in a subject, the method comprising administering (a) an SOS1 inhibitor and (b) a MET inhibitor to the subject, wherein (a) is administered before, simultaneously with, or after the administration of (b). In some embodiments, the cancer is an EGFR-mediated cancer, such as an EGFR-mediated cancer as described herein. In some embodiments, the MET inhibitor is selected from forretinib, AMG-458, tivantinib, crizotinib, cabozantinib, tepotinib, capmatinib, savolitinib, and gresatinib. In some embodiments, the MET inhibitor is selected from capmatinib, tepotinib, cabozantinib, and savolitinib. In some embodiments, the MET inhibitor is savolitinib. In some embodiments, the method further comprises administering an additional agent or additional therapy in combination with (a) an SOS1 inhibitor and (b) a MET inhibitor. In some embodiments, the additional agent is an EGFR inhibitor such as an EGFR inhibitor selected from gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, poziotinib, mobosertinib, diparereltinib, sambosertinib, BAY-2927088, BLU-451, BLU-945, STX-721, and zolifertinib. In some embodiments, the EGFR inhibitor is osimertinib. In some embodiments, additional therapies are selected from surgery, cell therapy, chemotherapy, and radiation.

[0111] Suitable agents that may be administered in combination with the target SOS1 inhibitor and MET inhibitor include osimertinib and other EGFR TKIs disclosed herein, other anticancer agents, anti-allergic agents, anti-nausea (or antiemetic) agents, analgesics, cytoprotective agents, immunomodulators, steroids, chemotherapeutic agents, and combinations thereof.

[0112] Examples of immunomodulatory agents include, but are not limited to, immunostimulants, checkpoint immunoblockers (e.g., blockers or inhibitors of immune checkpoint genes such as PD-1, PD-L1, CTLA-4, IDO, TIM3, LAG3, TIGIT, BTLA, VISTA, ICOS, KIRs, and CD39), radiotherapy agents, chemotherapeutic agents, and combinations thereof. In some embodiments, the immunostimulant is selected from the group consisting of IL-12, agonist-costimulatory monoclonal antibodies, and combinations thereof. In one embodiment, the immunostimulant is IL-12. In some embodiments, the agonist-costimulatory monoclonal antibody is selected from the group consisting of anti-4-1BB antibodies (e.g., urelumab, PF-05082566), anti-OX40 antibodies (pogalizumab, tavorixizumab, PF-04518600), anti-ICOS antibodies (BMS986226, MEDI-570, GSK3359609, JTX-2011), and combinations thereof. In one embodiment, the agonist-costimulatory monoclonal antibody is an anti-4-1BB antibody. In some embodiments, the checkpoint immunoblocker is selected from the group consisting of anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab, BMS-936559), anti-CTLA-4 antibodies (e.g., tremelimumab, ipilimumab), anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-LAG3 antibodies (e.g., C9B7W, 410C9), anti-B7-H3 antibodies (e.g., DS-5573a), anti-TIM3 antibodies (e.g., F38-2E2), and combinations thereof. In one embodiment, the checkpoint immunoblocker is an anti-PD-L1 antibody.

[0113] Examples of chemotherapeutic agents include anthracyclines (e.g., doxorubicin (e.g., liposomal doxorubicin)), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), and immune cell antibodies (e.g., alemtuzamab, gemtuzumab, rituximab, ofatumumab, tositumomab, brentz). Immunomodulators include ximab, antimetabolites (e.g., folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors (e.g., fludarabine)), TNFR glucocorticoid-inducible TNFR-related protein (GITR) agonists, proteasome inhibitors (e.g., acrasinomycin A, gliotoxin, or bortezomib), and thalidomide or thalidomide derivatives (e.g., lenalidomide). Additional chemotherapeutic agents intended for use in combination include busulfan (Myleran®), busulfan injection (Busulfex®), cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposomal injection (DepoCyt®), daunorubicin hydrochloride (Cerubidine®), daunorubicin crate liposomal injection (DaunoXome®), dexamethasone, and doxorubicin. Hydrochloride (Adriamycin®, Rubex®), Etoposide (Vepesid®), Fludarabine phosphate (Fludara®), Hydroxyurea (Hydrea®), Idamycin (Idamycin®), Mitoxantrone (Novantrone®), Gemtuzumab ozogamicin (Mylotarg®), Anastrozole (Arimidex®), Bicalutamide (Casodex®), Bleomycin sulfate (Blenoxane®), Busulfan injection (Busulfex®),Capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin) D, Cosmegan), Dexamethasone, Docetaxel (Taxotere®), 5-Fluorouracil (Adrucil®, Efudex®), Flutamide (Eulexin®), Tezacitibin, Gemcitabine (Difluorodeoxycytidine), Ifosfamide (IFEX®), Irinotecan (Camptosar®), L-Asparaginase (ELSPAR®), Leucovorin Calcium, Melphalan (Alkeran®), 6-Mercaptopurine (Purinethol®), Methotrexate (Folex®), Mitoxantrone (Novantrone®), Mylotarg, Examples include paclitaxel (Taxol®), pemetrexide (Alimata®), Phoenix (Yttrium90 / MX-DTPA), pentostatin, platinum-based chemotherapy, polyfeprosan 20 and carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazone®), topotecan hydrochloride for injection (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®), and vinorelbine (Navelbine®).

[0114] In some embodiments, the methods described herein include administering (a) an SOS1 inhibitor and (b) osimertinib, but (c) (1) an SHP2 inhibitor (e.g., 6-(4-amino-4-methylpiperidine-1-yl)-3-(2,3-dichlorophenyl)pyrazine-2-amine, RMC-4630, ERAS-601, TNO155, JAB-3068, IACS-13909 / BBP-398, SHP099, RMC-4550), (2) an inhibitor of wild-type RAS or mutant RAS, e.g., wild-type KRAS, wild-type HRAS, wild-type NRAS, mutant KRAS, mutant HRAS, mutant NRAS, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, KRAS G13D, KRAS G13C, KRAS G13V, or KRAS Q61H (e.g. LY3537982, JAB-21822, BBO-8520, D-1553, BI-1823911, RMC-9805, MRTX1133, MRTX849, AMG510, GDC-6036, AZD4625, JDQ443, RMC- 6291, RMC-6236, BI-2493, MK-1084, RMC-8839, SHR1127, JAB-21822, GFH925, IBI351, BPI-421286, JMKX1899, HBI-2438, D3S-001, GFH375, VS- (3) an additional drug selected from (4) 7375, RMC-7977, RMC-5127, FMC-376), and (4) MET inhibitors (e.g., foretinib, AMG-458, tivantinib, crizotinib, cabozantinib, tepotinib, capmatinib, savolitinib, glesatinib).

[0115] Any treatment method disclosed herein may involve administering SOS1 inhibitors and osimertinib or MET inhibitors in combination with or in conjunction with additional therapies. Appropriate treatments for EGFR-mediated diseases (including NSCLC) include surgery, radiotherapy, cell therapy, chemotherapy, bone marrow transplantation, and radiation.

[0116] Targeted combination therapies, including multiple different therapeutic agents (e.g., SOS1 inhibitors and osimertinib or MET inhibitors), can synergistically achieve one or more desired therapeutic effects or outcomes, including reduced progression of NSCLC. In some embodiments, reduced progression of EGFR-mediated cancer is demonstrated by stabilization of the disease, regression of the disease, improvement of lung function, or improvement of one or more symptoms of the cancer, such as improvement of one or more symptoms selected from cough, hemoptysis, chest pain or chest discomfort, dyspnea, wheezing, hoarseness, loss of appetite, unexplained weight loss, fatigue, dysphagia, and swelling of the facial and / or jugular veins. Subjects treated according to the methods of this disclosure may exhibit one or more desirable therapeutic outcomes described herein, any one of which may last for at least one month, for example, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least twelve months, at least eighteen months, at least twenty-four months, at least thirty months, at least thirty-six months, or longer. For example, subjects treated according to the methods of this disclosure may exhibit one or more of the following: (i) stabilization of the disease, (ii) regression of the disease, (iii) improvement of lung function, or (iv) improvement of one or more symptoms of cancer, any one or more of which may last for at least one month, for example, at least two months, at least three months, at least four months, at least five months, at least six months, at least seven months, at least eight months, at least nine months, at least ten months, at least eleven months, at least twelve months, at least eighteen months, at least twenty-four months, at least thirty months, at least thirty-six months, or longer.

[0117] The combination therapies disclosed herein may synergistically provide one or more superior benefits while achieving such desired effects or outcomes, including, but not limited to, (i) reducing the amounts of one, more or all of the therapeutic agents used in the combination therapy (e.g., dosing regimen, number of doses), (ii) avoiding, limiting or reducing one or more undesirable side effects associated with the use of any one of several different therapeutic agents when used in therapeutically effective or clinically approved doses, and (iii) enabling the use of EGFR TKIs that would otherwise be intolerable to the subject.

[0118] Administration of the combination therapies disclosed herein may mitigate any of the various undesirable side effects associated with osimertinib, including diarrhea, rash, nausea, stomatitis, vomiting, paronychia, fatigue, dry skin, loss of appetite, headache, anemia, pneumonia, pruritus, constipation, and cough. In some embodiments, diarrhea, rash, nausea, dry skin, and / or paronychia can be mitigated. Combination therapies with SOS1 inhibitors disclosed herein may enable the administration of osimertinib, which would otherwise be unacceptable to the subject. Combination therapies with subject SOS1 inhibitors may enable more frequent dosing regimens with osimertinib, which would otherwise be too toxic or unacceptable to subjects requiring such treatment.

[0119] The combination therapies disclosed herein utilize osimertinib at doses that are not optimal when used alone, but when used in combination with the SOS1 inhibitors disclosed herein, they result in overall therapeutic efficacy (e.g., enhanced one or more desirable therapeutic outcomes and / or reduced undesirable side effects). In some embodiments, the combination therapy utilizes osimertinib at a dose lower than that approved for treating human subjects for a given indication (e.g., below the therapeutic dose). In some embodiments, the below-therapeutic dose is less than 95% of the approved dose of osimertinib, for example, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of the approved dose of osimertinib. For example, the below-therapeutic dose of osimertinib is less than the dose of 80 mg orally once daily that is approved as adjuvant therapy for early NSCLC. In some embodiments, sub-therapeutic doses of osimertinib are less than the approved dose of 80 mg orally once daily for metastatic NSCLC. Sub-therapeutic doses of osimertinib may be less than 90% of the approved dose of 80 mg orally once daily for adjuvant therapy in early-stage NSCLC, or less than 90% of the approved dose of 80 mg orally once daily for metastatic NSCLC, for example, less than 72 mg orally once daily for adjuvant therapy in early-stage NSCLC, or less than 72 mg orally once daily for metastatic NSCLC. In some embodiments, osimertinib is administered in combination with an SOS1 inhibitor disclosed herein at a dose of 80 mg per day. In some embodiments, osimertinib is administered in combination with an SOS1 inhibitor disclosed herein at a dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, or 240 mg per day.

[0120] In any implementation of the methods of this disclosure, the SOS1 inhibitor may be administered in combination with osimertinib in a dose of at least 5 mg per day, for example, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, 220 mg, 240 mg, 260 mg, 280 mg, 300 mg, 320 mg, 340 mg, 360 mg, 380 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg per day. In some embodiments, the SOS1 inhibitor is combined with osimertinib, for example, 80 mg of osimertinib, in doses ranging from 5 to 1000 mg, for example, approximately 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, 200 mg, and 220 mg. g is administered in doses of approximately 240 mg, 260 mg, 280 mg, 300 mg, 320 mg, 340 mg, 360 mg, 380 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg. In some embodiments, the SOS1 inhibitor is administered once daily in oral form.

[0121] In certain embodiments, the Disclosure provides a method for treating cancer in subjects requiring cancer treatment. The method may include administering to the subject a pharmaceutical composition comprising an effective amount of a small molecule SOS1 inhibitor, wherein the SOS1 inhibitor inhibits the proliferation of NSCLC cell lines at an IC50 of approximately 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, less than 5 nM, or lower, as confirmed by a proliferation inhibition assay using NSCLC cell lines. In some embodiments, the SOS1 inhibitor is Ba / F3-EGFR_Ex20_ASV insertion, Ba / F3-EGFR_L858R / T790M, PC9-EGFR Ex19 E746_A750 deletion, H1975-EGFR NSCLC cell lines selected from the group consisting of L858R / T790M, Ba / F3-EGFR-V769_D770insASV, Ba / F3-EGFR_D770_N771insNPH, H1993, LU0858, LU0387, LU3075, H3122, and H2228 are inhibited with an IC50 of less than approximately 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, or lower. In some embodiments, the SOS1 inhibitor inhibits the proliferation of NSCLC cell lines with an IC50 at least 10, 50, or 100 times lower than that of BI3406 or MRTX0902. In some embodiments, SOS1 inhibitors synergistically inhibit the proliferation of NSCLC cell lines when used in combination with osimertinib. In some embodiments, SOS1 inhibitors synergistically inhibit the proliferation of NSCLC cell lines when used in combination with MET inhibitors.In some embodiments, SOS1 inhibitors are characterized in that, in in vitro proliferation inhibition assays using NSCLC cells, SOS1 inhibitors at concentrations of less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM are applied in combination with osimertinib at an IC50 molar concentration, synergistically inhibiting the proliferation of NSCLC cells in combination with osimertinib, resulting in at least approximately 80% proliferation inhibition. In some embodiments, as confirmed in in vitro proliferation inhibition assays using NSCLC cells, SOS1 inhibitors at concentrations of less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM are characterized in that, when applied in combination with osimertinib at an IC10 molar concentration, the SOS1 inhibitors synergistically increase the rate of cell proliferation inhibition from approximately 10% to at least approximately 50%. In some embodiments, in in vitro proliferation inhibition assays using NSCLC cells, SOS1 inhibitors at concentrations of less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM are characterized in that, when applied in combination with osimertinib at an IC50 molar concentration, the SOS1 inhibitors synergistically increase the rate of cell proliferation inhibition from approximately 50% to at least approximately 80%.

[0122] In yet another embodiment, the Disclosure provides a method for reducing the proliferation of cells containing EGFR mutations. The method comprises administering to cells (a) a small molecule SOS1 inhibitor as disclosed herein and (b) osimertinib, wherein the administration of (a) and (b) synergistically inhibits the proliferation of NSCLC cells, as demonstrated by achieving equivalent or higher proliferation inhibition when (1) less than 90% of the SOS1 inhibitor is administered compared to the amount required for the SOS1 inhibitor when administered alone, or (2) less than 90% of the osimertinib is administered compared to the amount required for osimertinib when administered alone. In some embodiments, osimertinib is administered at about 80%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, or less than 10% of the amount required to achieve equivalent or higher proliferation inhibition. In some embodiments, osimertinib is administered in doses of less than 80 mg per day, for example, less than 75 mg per day, less than 70 mg per day, less than 65 mg per day, less than 60 mg per day, less than 55 mg per day, less than 50 mg per day, less than 45 mg per day, less than 40 mg per day, less than 35 mg per day, less than 30 mg per day, less than 25 mg per day, less than 20 mg per day, less than 15 mg per day, or less than 10 mg per day. In some embodiments, osimertinib is administered in doses of 80 mg per day.

[0123] compound The MET inhibitors used in this disclosure may be any MET inhibitor known in the art and may include any entity that, upon administration to a subject, causes downregulation of MET in the subject. For example, suitable MET inhibitors may be selected from a variety of molecular types. In particular, MET inhibitors may be biological or chemical compounds such as simple or complex organic or inorganic molecules, peptides, peptide mimes, proteins (e.g., antibodies), liposomes, or polynucleotides (e.g., small interfering RNA, short hairpin RNA, microRNA, antisense, aptamers, ribozymes, triple helices). In some embodiments, the methods disclosed herein utilize small MET inhibitors. Exemplary MET inhibitors for use in such combinations include one or more of forretinib, AMG-458, tivantinib, crizotinib, cabozantinib, tepotinib, capmatinib, savolitinib, and gresatinib. In some embodiments, the MET inhibitor is selected from capmatinib, tepotinib, cabozantinib, and savolitinib. In some embodiments, the MET inhibitor is savolitinib.

[0124] The SOS1 inhibitors used in this disclosure may be any SOS1 inhibitor known in the art and may include any entity that, upon administration to a subject, causes downregulation of SOS1 in the subject. For example, suitable SOS1 inhibitors may be selected from a variety of molecular types. In particular, SOS1 inhibitors may be biological or chemical compounds such as simple or complex organic or inorganic molecules, peptides, peptide mimes, proteins (e.g., antibodies), liposomes, or polynucleotides (e.g., small interfering RNA, short hairpin RNA, microRNA, antisense, aptamers, ribozymes, triple helices). In some embodiments, the methods disclosed herein utilize small molecular weight SOS1 inhibitors. As used herein, the term “small molecular weight” refers to small molecular weight organic compounds such as compounds having molecular weights less than 1500 g / mol, less than 1250 g / mol, less than 1000 g / mol, or less than 750 g / mol. Many compounds are known to inhibit SOS1 (for example, the compound in WO2005 / 097119, which is incorporated in whole herein by reference).

[0125] In some embodiments, a small molecule SOS1 inhibitor may be conjugated to a degradation tag. The degradation tag may be configured to bind to a degradation moiety having the ability to degrade at least a portion of the target moiety to which the degradation tag binds. In some embodiments, the target moiety is SOS1 or a substrate of SOS1.

[0126] In some embodiments, the SOS1 inhibitor in question disrupts the interaction between SOS1 and KRAS with an IC50 of less than approximately 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, less than 0.1 nM, or even less than that. In some embodiments, the SOS1 inhibitor is at least 5 times potent than BI-3406, MRTX0902, BAY293, RMC-5845, or BI-1701963, for example, at least 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or 100 times potent, when confirmed using the Ras-SOS interaction assay described in Example 3. In some embodiments, the target SOS1 inhibitor inhibits the proliferation of cancer cells, such as NSCLC cell lines, with an IC50 of less than approximately 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, or even less than that, when confirmed in proliferation inhibition assays using NSCLC cell lines. In some embodiments, the SOS1 inhibitors are Ba / F3-EGFR_Ex20_ASV insertion, Ba / F3-EGFR_L858R / T790M, PC9-EGFR Ex19 E746_A750 deletion, H1975-EGFR NSCLC cell lines selected from the group consisting of L858R / T790M, Ba / F3-EGFR-V769_D770insASV, Ba / F3-EGFR_D770_N771insNPH, H1993, LU0858, LU0387, LU3075, H3122, and H2228 are inhibited with an IC50 of less than approximately 500 nM, less than 400 nM, less than 300 nM, less than 200 nM, less than 100 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, or lower. In some embodiments, the SOS1 inhibitor inhibits the proliferation of NSCLC cell lines RMC-5845, BI-1701963, [ka] In some embodiments, SOS1 inhibitors inhibit the proliferation of NSCLC cell lines with an IC50 at least 10 times, 50 times, 100 times, 200 times, 300 times, 500 times, or 1000 times lower than SOS inhibitors described in WO2021092115, WO2018172250, WO2019201848, WO2019122129, WO2018115380, WO2021127429, WO2020180768, or WO2020180770. Each of those documents is incorporated herein by reference in whole for all purposes. In some embodiments, SOS1 inhibitors, when used in combination with osimertinib or MET inhibitors, synergistically inhibit the proliferation of cancer cells such as NSCLC cell lines.

[0127] In some embodiments, SOS1 inhibitors are characterized in that, in in vitro proliferation inhibition assays using NSCLC cells, SOS1 inhibitors at concentrations of less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, less than 1 nM, less than 0.5 nM, less than 0.4 nM, less than 0.3 nM, less than 0.2 nM, or less than 0.1 nM are applied in combination with osimertinib or a MET inhibitor at an IC50 molar concentration, synergistically inhibiting the proliferation of NSCLC cells in combination with osimertinib or a MET inhibitor, resulting in at least approximately 80% proliferation inhibition. In some embodiments, as confirmed in in vitro proliferation inhibition assays using NSCLC cells, SOS1 inhibitors with concentrations of less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM are characterized in that, when applied in combination with osimertinib or MET inhibitors applied at an IC10 molar concentration, the SOS1 inhibitors synergistically increase the rate of cell proliferation inhibition from approximately 10% to at least approximately 50%. In some embodiments, in an in vitro proliferation inhibition assay using NSCLC cells, when an SOS1 inhibitor at concentrations less than approximately 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM, or less than 1 nM is applied in combination with osimertinib or a MET inhibitor at an IC50 molar concentration, the SOS1 inhibitor synergistically increases the rate of cell proliferation inhibition from approximately 50% to at least approximately 80%.

[0128] Compounds of formula (I) disclosed herein, including compounds of formula (IA), (IB), (I-1), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), (I-E1), (II-B), (II-C), and (III), or their pharmaceutically acceptable salts or solvates, are SOS regulators and have a wide range of applications in therapeutic, diagnostic, and other biomedical research.

[0129] In certain embodiments, this disclosure relates to compounds of formula (I): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] C 5-7 Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, [ka] is absent, or C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains one or more R 11a It is optionally replaced by, L 1 is a bond, C 1-6 Alkylene and C 1-6 Selected from haloalkylenes, L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, L 3C 1-10 Alkilen, C 2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by, D is absent, or C 3-12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which has one or more R 11d It is optionally replaced by, L 4 C 1-10 Alkilen, C 2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by, W 2 N(R) 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 N(R) 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 N(R) 5b ), N, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 6 N(R) 6b ), N, C(R 6 ), C(R 6 )(R 6a ), and C(O) are selected, W 7 N(R) 7b ), N, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, W 8 N(R) 8b ), N, C(R 8 ), C(R 8 )(R 8a ), and C(O) are selected, W 9 N, C(R 9 ), and C are selected, W 10 N, C(R 10 ), and C are selected, R 1 is one or more R 11c C is optionally replaced by 1-3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a These are hydrogen, halogen, -CN, and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15, -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 2b and R 8b These are hydrogen, -CN, and C respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12)(R 13 )、-S(=O)(=NH)N(R 12 )(R 13 )、-CH2C(O)N(R 12 )(R 13 )、-CH2N(R 14 )C(O)R 15 、-CH2S(O)2R 15 、and -CH2S(O)2N(R 12 )(R 13 ) are independently selected, and each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle and 3-10 membered heterocycle are independently optionally substituted with 1, 2, or 3 R 20 , R 3b , R 4b , R 5b , R 6b , and R 7b are each independently a bond to L 2 , hydrogen, -CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, 3-10 membered heterocycle, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 , -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 , -CH2S(O)2R15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 9 and R 10 These are hydrogen and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 A carbon ring is independently selected from a 3- to 10-membered heterocycle and a -CH2- (3- to 10-membered heterocycle), and each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 The carbon ring, 3- to 10-membered heterocycle, and -CH2- (3- to 10-membered heterocycle) independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11 , R 11a , and R 11d In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 , -S(O)₂R 15 , -S(O)₂N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH₂C(O)N(R 12 )(R 13 ), -CH₂N(R 14 )C(O)R 15 , -CH₂S(O)₂R 15 , -CH₂S(O)₂N(R 12 )(R 13 ), -CH₂N(R 12 )S(O)₂(R 13 ), and -P(O)(R 17 )(R 17a ) are independently selected, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, and 3-10 membered heterocycle are optionally substituted with 1, 2, or 3 R 20 , R 11b at each occurrence is halogen, oxo, -CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11c In each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) were selected independently of, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0130] In certain embodiments, this disclosure relates to compounds of formula (I): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] C 5-7 Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, [ka] is absent, or C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains one or more R 11a It is optionally replaced by, L 1 is a bond, C 1-6 Alkylene and C 1-6 Selected from haloalkylenes, L 2 C 5-25Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, W 2 N(R) 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 N(R) 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 N(R) 5b ), N, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 6 N(R) 6b ), N, C(R 6 ), C(R 6 )(R 6a ), and C(O) are selected, W 7 N(R) 7b ), N, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, W 8 N(R) 8b ), N, C(R 8 ), C(R8 )(R 8a ), and C(O) are selected, W 9 N, C(R 9 ), and C are selected, W 10 N, C(R 10 ), and C are selected, R 1 is one or more R 11c C is optionally replaced by 1-3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a These are hydrogen, halogen, -CN, and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 2b and R 8b These are hydrogen, -CN, and C respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 The carbon ring and the 3- to 10-membered heterocycle independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , R 5b , R 6b , and R 7b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20It is optionally replaced by, R 9 and R 10 These are hydrogen and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 A carbon ring is independently selected from a 3- to 10-membered heterocycle and a -CH2- (3- to 10-membered heterocycle), and each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 The carbon ring, 3- to 10-membered heterocycle, and -CH2- (3- to 10-membered heterocycle) independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11 and R 11a In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14)C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11c In each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) were selected independently of, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24)S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0131] In some embodiments, the compound of formula (I) is the compound of formula (IA): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0132] In some embodiments, the compound of formula (IA) is [ka] It is a compound selected from among them.

[0133] In some embodiments, the compound of formula (I) is replaced with the compound of formula (IB), for example, the compound of formula (I-B1) or (I-B2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0134] In some embodiments, the compound of formula (IB) is [ka] It is a compound selected from among them.

[0135] In some embodiments, the compound of formula (I) is a compound of formula (IC), for example, a compound of formula (I-C1), (I-C2), or (I-C3): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0136] In some embodiments, the compound of formula (IC) is [ka] It is a compound selected from among them.

[0137] In some embodiments, the compound of formula (I) is replaced with the compound of formula (ID), for example, the compound of formula (I-D1) or (I-D2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0138] In some embodiments, the compound of formula (ID) is [ka] It is a compound selected from among them.

[0139] In some embodiments, the compound of formula (I) is replaced with the compound of formula (IE), for example, the compound of formula (I-E1): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0140] In some embodiments, the compound of formula (IE) is [ka] It is a compound selected from among them.

[0141] In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 is N. In some embodiments, W 3 N(R) 3b), N, C(R 3 ), and C(O) are selected, for example, from NCH3, N, CH, CCH3, and C(O). In some embodiments, W 3 C(R 3 ) and C(O) are selected, for example, CH, CCH3 and C(O). In some embodiments, W 3 is CH. In some embodiments, W 3 This is CCH3. In some embodiments, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected, for example, N(R 4b ), N, C(R 4 ), and C(O)(in this case, R 4b and R 4 Each is independent of L 2 Selected from (a combination with) in some embodiments, W 4 N(R) 4b ) and N are selected, for example, N(R 4b )(In this case, R 4b L 2 Selected from (a combination with) in some embodiments, W 4 is N. In some embodiments, W 5 N(R) 5b ), N, C(R 5 ), and C(O) are selected, for example, N(R 5b ), NCH3, N, CH, C(R 5 ), and C(O)(in this case, R 5b and R 5 Each is independent of L 2 Selected from (a combination with) in some embodiments, W 5 N(R) 5b ), N, and C(R 5 ) is selected from, for example, N(R 5b ), NCH3, N, CH, and C(R 5 )(In this case, R 5b and R 5 Each is independent of L 2 Selected from (a combination with) in some embodiments, W5 N(R) 5b ), and C(R 5 ) is selected from, for example, N(R 5b ), NCH3, and CH(in this case, R 5b L 2 Selected from (a combination with) in some embodiments, W 5 N(R) 5b ) In some embodiments, W 6 C(R 6 ) and C(O) are selected, for example, COCH -3 CH, C(R 6 ), and C(O)(in this case, R 6 L 2 Selected from (a combination with) in some embodiments, W 6 is C(O). In some embodiments, W 7 C(R 7 ) and for example, W 7 C(R 7 )(In this case, R 7 L 2 It is a combination with W. 7 R 7 It is not hydrogen, C(R 7 ) and for example, R 7 C 3-10 Cycloalkyl, 3-10 member heterocycloalkyl, and -OR 12 Selected from 、 C 3-10 Cycloalkyl and 3- to 10-membered heterocycloalkyl groups have 1, 2, or 3 R 20 It is optionally replaced by W. In some embodiments, 8 C(R 8 ) and for example, W 8 is CH. In some embodiments, W 9 C is C. In some embodiments, W 10 It is C.

[0142] In some embodiments, for compounds of formula (I), (IA), (IC), (ID), or (IE), W 2N is W 3 N(R) 3b ) and W 4 C(O) and W 9 and W 10 Each of these is C, for example, W 2 N is W 3 It is NCH3, and W 4 C(O) and W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IB), (IC), (ID), or (IE), W 2 N is W 3 C(O) and W 4 N(R) 4b ) and W 9 and W 10 Each of these is C, for example, W 2 N is W 3 C(O) and W 4 N(R) 4b )(In this case, R 4b L 2 It is a combination with W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IC), (ID), or (IE), W 2 N is W 3 C(R 3 ) and W 4 N is W 9 and W 10 Each of these is C, for example, W 2 N is W 3 is CH or CCH3, W 4 N is W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), W 5 C(R 5 ) and W 6 C(R 6 ) and W 7 C(R7 ) and W 8 C(R 8 ) and W 9 and W 10 Each of these is C, for example, W 5 CH or C(R 5 )(In this case, R 5 L 2 It is a combination with W 6 CH or C(R 6 )(In this case, R 6 L 2 It is a combination with W 7 C(R 7 ) and W 8 CH is W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IB), (IC), or (IE), W 5 N(R) 5b ) and W 6 C(O) and W 7 C(R 7 ) and W 8 C(R 8 ) and W 9 and W 10 Each of these is C, for example, W 5 This is NCH3 or N(R 5b )(In this case, R 5b L 2 It is a combination with W 6 C(O) and W 7 C(R 7 ) and W 8 CH is W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IB), (ID), or (IE), W 5 N is W 6 C(R 6 ) and W 7 C(R 7 ) and W 8 C(R 8 ) and W9 and W 10 Each of these is C, for example, W 5 is N and W 6 COCH3, CH, or C(R 6 )(In this case, R 6 L 2 It is a combination with W 7 C(R 7 ) and W 8 However, it is CH and W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 N is W 3 N(R) 3b ), N, C(R 3 ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected, W 5 N(R) 5b ), N, and C(R 5 ) is selected from, W 6 C(R 6 ) and C(O) are selected, W 7 C(R 7 ) and W 8 C(R 8 ) and W 9 and W 10 Each of these is C, for example, W 2 N is W 3 It is selected from NCH3, N, CH, CCH3, and C(O), W 4 N(R) 4b ), N, C(R 4 ), and C(O)(in this case, R 4b and R 4 Each is independent of L 2 Selected from (which is a combination with W) 5 N(R) 5b ), NCH3, N, CH, and C(R 5 )(In this case, R 5b and R 5Each is independent of L 2 Selected from (which is a combination with W) 6 COCH -3 CH, C(R 6 ), and C(O)(in this case, R 6 L 2 Selected from (which is a combination with W) 7 C(R 7 ) and W 8 CH is W 9 and W 10 Each of these is C. In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), W 2 N is W 3 C(R 3 ) and C(O) are selected, W 4 N(R) 4b ) and N are selected, W 5 N(R) 5b ) and C(R 5 ) is selected from, W 6 C(R 6 ) and C(O) are selected, W 7 C(R 7 ) and W 8 CH is W 9 and W 10 Each of these is C, for example, W 2 N is W 3 It is selected from CH, CCH3, and C(O), W 4 N(R) 4b ) and N (in this case, R 4b L 2 Selected from (which is a combination with W) 5 N(R) 5b ), NCH3, CH, and C(R 5 )(In this case, R 5b and R 5 Each is independent of L 2 Selected from (which is a combination with W) 6 COCH -3 CH, C(R 6 ), and C(O)(in this case, R 6 L2 Selected from (which is a combination with W) 7 C(R 7 ) and W 8 CH is W 9 and W 10 Each of them is C.

[0143] In some embodiments, for the compound of formula (I), [ka] teeth, [ka] Selected from. In some embodiments, [ka] teeth, [ka] [ka] Selected from. In some embodiments, [ka] teeth, [ka] Selected from. In some embodiments, [ka] teeth, [ka] Selected from. In some embodiments, [ka] teeth, [ka] For example, [ka] In some embodiments, [ka] teeth, [ka] For example, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] For example, [ka] In some embodiments, [ka] teeth, [ka] Selected from. In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] That is the case.

[0144] In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a These are hydrogen, halogen, -CN, and C, respectively. 1-3 Alkyl, C 1-3 Independently selected from haloalkyl, -OH, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a Each is selected from hydrogen and -CH3, and is selected independently of hydrogen, for example.

[0145] In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), R 3 , R 4 , R 5 , and R 6 Each is independent of L 2Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-6 Carbon rings and 3- to 6-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by; R 7 L 2 The combination with C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected independently of C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 3 , R 4 , R 5 , and R 6 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, R 7 L2 The combination with C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected independently of C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 3 , R 4 , R 5 , and R 6 Each is L 2 The bond is selected from hydrogen, -CH3, and -OCH3, R 7 L 2 The combination with C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected independently of C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is being replaced by an arbitrary choice.

[0146] In some embodiments, for compounds of formula (I), (IA), (IB), (IC), (ID), or (IE), R 2b and R 8b These are hydrogen and C, respectively. 1-3 Alkyl, for example, is independently selected from hydrogen and -CH3. In some embodiments, R3b , R 4b , R 5b , R 6b , and R 7b Each is L 2 Bonding with hydrogen, and C 1-3 Selected from alkyl groups, for example, L 2 The bond with, hydrogen, and -CH3 are independently selected. In some embodiments, R 3b , R 4b , R 5b , R 6b , and R 7b Each is L 2 The coupling with and is selected independently of -CH3. In some embodiments, R 3b , R 4b , R 5b , R 6b , and R 7b Each is L 2 It is selected independently of the coupling with R. In some embodiments, 9 and R 10 Each of them is hydrogen.

[0147] L 2 However, -L 3 -DL 4 For the compound of formula (I) -, R 3 , R 4 , R 5 , R 6 , R 7 , R 3b , R 4b , R 5b , R 6b , or R 7b L for one of the 2 The choice of combination with is -L 3 -DL 4 -and, especially L 4 It is understood that this essentially involves a union with L. To avoid any doubt, it should be added that L 2 R including a bond with 3 , R 4 , R 5 , R 6 , R 7 、 R 3b , R 4b , R 5b, R 6b , and / or R 7b Any enumeration of is also "L 4 This can be considered to include "combination with".

[0148] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 C 1-3 Alkyl and C -1-3 Haloalkyls are selected from, for example, -CH3, -CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, CH2CH2F, -CH2CHF2, and -CH2CF3. In some embodiments, R 1 C 1-3 From alkyl groups, for example, -CH3 and -CH2CH3 are selected. In some embodiments, R 1 is -CH3. In some embodiments, R 1 is (R)-CH3. In some embodiments, R 1 This is (S)-CH3.

[0149] In some embodiments, for compounds of formula (I), (IB), (IC), (I-C1), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 3 Hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15, and -S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-6 Carbon rings and 3- to 6-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by R. In some embodiments, 3 Hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 3 These are hydrogen, halogen, -CN, -OR 12 , and 1, 2, or 3 R 20 C is optionally replaced by 1-6 Selected from alkyl groups. In some embodiments, R 3 This is 1, 2, or 3 R 20 C is optionally replaced by 1-6 It is alkyl. In some embodiments, R 3 is hydrogen or -CH3. In some embodiments, R 3 is hydrogen. In some embodiments, R 3 It is -CH3.

[0150] In some embodiments, for compounds of formula (I), (IB), (IC), (I-C2), (ID), or (IE), R 3b is hydrogen and C 1-3 From alkyl groups, for example, hydrogen and -CH3 are selected. In some embodiments, R 3b is -CH3. In some embodiments, R 3b It is hydrogen.

[0151] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B2), (ID), (I-D2), (IE), or (I-E1), R 5 Hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-6 Carbon rings and 3- to 6-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by R. In some embodiments, 5 Hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 5 is hydrogen, -OR 12 , and 1, 2, or 3 R 20 C is optionally replaced by 1-6 Selected from alkyl groups. In some embodiments, R 5 is hydrogen or -CH3. In some embodiments, R 5 is hydrogen. In some embodiments, R 5 It is -CH3.

[0152] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (ID), or (IE), R 5b is hydrogen and C 1-3 From alkyl groups, for example, hydrogen and -CH3 are selected. In some embodiments, R 5b It consists of hydrogen and 1, 2, or 3 R atoms. 20 C is optionally replaced by 1-6 Selected from alkyl groups. In some embodiments, R 5b is -CH3. In some embodiments, R5b is hydrogen. In some embodiments, R 5b L 2 It is a combination of the two.

[0153] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B2), (IC), (I-C3), (IE), or (I-E1), R 6 Hydrogen, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-6 Carbon rings and 3- to 6-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by R. In some embodiments, 6 Hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 6 is hydrogen, -OR 12 , and 1, 2, or 3 R 20 C is optionally replaced by 1-6 Selected from alkyl, R 12 C 1-6 Selected from alkyl groups. In some embodiments, R 6 R is selected from hydrogen and -OCH3. In some embodiments, R 6 is hydrogen. In some embodiments, R6 It is -OCH3.

[0154] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by R. In some embodiments, 7 C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 7 C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 member heterocycloalkyl, and -N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Cycloalkyls and 3- to 10-membered heterocycloalkyls have 1, 2, or 3 R 20 It is optionally replaced by R. In some embodiments, 7 This is 1, 2, or 3 R 20 A 3- to 10-membered heterocycloalkyl group optionally substituted with R, for example, 7 This is 1, 2, or 3 R 20 It is a 4-6 member heterocycloalkyl group that is optionally substituted with R. In some embodiments, 7 This is 1, 2, or 3 R 20 A 3- to 10-membered heterocycloalkyl group optionally substituted with, the heterocycloalkyl group comprising at least one O, N, or S atom, for example, one O atom, one or two N atoms, or one S atom. In some embodiments, R 7 This is 1, 2, or 3 R 20 A 3-6 member heterocycloalkyl group optionally substituted with, where the heterocycloalkyl group contains S(O)2. In some embodiments, R 7 This is 1, 2, or 3 R 20 C is optionally replaced by 3-10 It is a cycloalkyl, for example, R 7 This is 1, 2, or 3 R 20 C is optionally replaced by 3-6 It is cycloalkyl. In some embodiments, R 7 This is one R 20 C is optionally replaced by 3-4 It is a cycloalkyl, and optionally R 20 is -CN. In some embodiments, R 7This is 1, 2, or 3 R 20 C is optionally replaced by 1-6 It is alkyl, for example, R 7 is one or two R 20 C replaced by 1-6 It is alkyl. In some embodiments, R 7 is -N(R 12 )(R 13 ) is. In some embodiments, R 7 is -OR 12 For example, -O (3-6 member heterocycloalkyl). In some embodiments, R 7 is replaced by at least one -CN. In some embodiments, R 7 is non-substitutable. In some embodiments, R 7 C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 7 C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which is oxo, -CN, and C 1-6 It is optionally substituted with one, two, or three substituents selected from alkyl groups. In some embodiments, R 7 These are oxo, -CN, and C 1-3 It is a 4- to 6-membered heterocycloalkyl group substituted with one, two, or three substituents selected from alkyl groups. In some embodiments, R 7 These are oxo, -CN, and C 1-3 C substituted with 1, 2, or 3 substituents selected from alkyl groups 3-4 It is a cycloalkyl group.

[0155] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)(NR 12 )R 15 -S(O)2N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)(NR 12 )R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by R. In some embodiments, 7 C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)(NR 12 )R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 7 This is 1, 2, or 3 R 20A 3-6 member heterocycloalkyl group is optionally substituted with S(O)(NR 12 ) includes.

[0156] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 teeth, [ka] And in the formula, n1 is an integer between 1 and 3. n2 is an integer between 0 and 2. n3 is an integer between 0 and 2. n4 is either 0 or 1. X is -O-, -S(O2)-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-,-CH(R 20 )-,-C(R 20 )2-, -NR 12 -, -CH(N(R 12 )(R 13 ))-,-CH(C(O)N(R 12 )(R 13 ))-, and -CH(S(O)2N(R 12 )(R 13 )- Selected from, R 12 , R 13 , and R 20 This is defined elsewhere in this specification, Selectively, two R 20 Base, or R 20 and R 12 These atoms bond together with the atoms they are connected to to form a ring. For example, R 7 teeth, [ka] It can be selected from the following. In some embodiments, X is -O-, -S(O)2-, -S(O)(NR12 )-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-,-CH(R 20 )-,-C(R 20 )2-, -NR 12 -, -CH(N(R 12 )(R 13 ))-,-CH(C(O)N(R 12 )(R 13 ))-, and -CH(S(O)2N(R 12 )(R 13 )- Selected from.

[0157] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), or (I-D2), R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] That is the case.

[0158] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 8 It consists of hydrogen, halogen, and 1, 2, or 3 R atoms. 20 C is optionally replaced by 1-6 Selected from alkyl groups. In some embodiments, R 8 It is hydrogen.

[0159] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), [ka] C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, for example, C 5-7Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, [ka] C 5-7 Selected from cycloalkyl, 5-7 member heterocycloalkyl, 5-7 member heteroaryl, and phenyl, each of which contains one or more R 11 It is optionally replaced by, [ka] These are selected from phenyl, pyridyl, and thiophenyl, each of which has one or more R 11 It is optionally replaced by, [ka] teeth, [ka] Selected from, for example, [ka] Selected from. In some embodiments, R 11 If present, in each occurrence, it is independently selected from fluorine and -CH3. In some embodiments, [ka] teeth, [ka] Selected from, for example, [ka] Selected from. In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] That is the case.

[0160] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 1 C 1-6 Alkylene and C 1-6 Haloalkylenes, for example, C 1-3 Alkylene and C 1-3 Selected from haloalkylenes. In some embodiments, L 1 is bond and C 1-3 Selected from haloalkylenes. In some embodiments, L 1 C 1-3 Haloalkylenes, for example, -CF2-, -CF2CH2-, or -CF2CH2CH2-. In some embodiments, L 1 C 1-2 It is a haloalkylene, for example, -CF2- or -CF2CH2-. In some embodiments, L 1 is -CF2-. In some embodiments, L 1 is -CF2CH2-. In some embodiments, L 1is -CF2CH2CH2-. In some embodiments, L 1 This is a bond. In some embodiments, L 1 These are bonded, -O-, -NR 12 -, -S-, C 1-6 Alkilen, C 1-6 Selected from haloalkylenes and 2-6 member heteroalkylenes, C 1-6 Alkilen, C 1-6 Haloalkylenes and 2-6 member heteroalkylenes are one or more R 11b It is optionally replaced by L. In some embodiments, 1 -O-, -NR 12 -, -S-, and 2- to 6-membered heteroalkylenes are selected, and the 2- to 6-membered heteroalkylenes are one or more R 11b It is optionally replaced by L. In some embodiments, 1 is one or more R 11b For example, 1, 2, or 3 R 11b C is optionally replaced by 1-6 It is alkylene. 1 These are bonded, -O-, -NR 12 -, -S-, C 1-3 Alkilen, C 1-3 Selected from haloalkylenes and 2-3 member heteroalkylenes, C 1-3 Alkilen, C 1-3 Haloalkylenes and 2-3 member heteroalkylenes are one or more R 11b It is optionally replaced by L. In some embodiments, 1 -O-, -NR 12 -, -S-, and 2-3 member heteroalkylenes are selected, and the 2-3 member heteroalkylene is one or more R 11b It is optionally replaced by L. In some embodiments, 1 is one or more R 11b For example, 1, 2, or 3 R 11b C replaced by 1-3 It is alkylene.

[0161] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), [ka] is absent, or C 4-8 Selected from carbon rings and 4- to 8-membered heterocycles, each of which contains one or more R 11a It is optionally replaced by, [ka] is either absent or selected from phenyl and 4- to 8-membered heterocycles, each of which has one or more R 11a It is optionally replaced by, [ka] These are selected from phenyl and 4- to 8-membered heterocycles, each of which has one or more R 11a It is optionally replaced by, [ka] is either absent, or selected from phenyl, azetidine, pyrrolidine, and piperidine, each of which has one or more R 11a It is optionally replaced by, [ka] These are selected from phenyl, azetidine, pyrrolidine, and piperidine, each of which is one or more R 11a It is optionally replaced by, [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. In some embodiments, [ka] is one or more R 11a Phenyl is optionally substituted with phenyl. In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] is one or more R 11a Azetidine is optionally substituted with . In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] is one or more R 11a It is a pyrrolidine that is optionally substituted with. In some embodiments, [ka] is one or more R 11a It is a piperidine that is optionally substituted with. In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] It is non-substitutable. In some embodiments, [ka] is one or more R 11a For example, 1, 2, or 3 R 11a It is replaced by R. In some embodiments, 11a In each occurrence, halogen, -CN, C 1-6 Alkyl, C 3-6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -N(R 14 )S(O)2R 15 ,-C(O)N(R 12)(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) is selected independently of C 1-6 Alkyl, C 3-6 Carbon rings and 3- to 6-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R. In some embodiments, 11a In each occurrence, halogen, C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyls. In some embodiments, R 11a In each occurrence, C 1-6 Selected independently of alkyl. In some embodiments, R 11a It is -CH3.

[0162] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 5-25 Alkilen, C 5-25 Selected from alkenylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 Together with the atoms to which it is bonded, it forms a 16-36 membered macrocyclic ring, for example, a 16-24 membered macrocyclic ring. In some embodiments, L 2 C 6-15 Alkilen, C 6-15Alkenylene, C 6-15 Selected from alkylylenes, 6-15 member heteroalkylenes, and 6-15 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 Alkenylenes or heteroalkenylenes contain one carbon-carbon double bond. In some embodiments, L 2 The heteroalkylene or heteroalkenylene contains at least one oxygen or nitrogen atom. In some embodiments, L 2 The heteroalkylene or heteroalkenylene contains at least one basic nitrogen. In some embodiments, L 2 C 5-9 Alkilen, C 5-9 Selected from alkenylenes and 5- to 9-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 6-9 Alkilen, C 6-9 Selected from alkenylenes and 6- to 9-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 5-8 Alkilen, C 5-8 Selected from alkenylenes and 5- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 6-8 Alkilen, C 6-8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which contains one or more R 11bIt is optionally replaced by L. In some embodiments, 2 C 6-8 Alkylene and C 6-8 Selected from alkenylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 The compounds are selected from C6 alkylenes and C6 alkenylenes, each of which has one or more R 11b It is optionally replaced by L. In some embodiments, 2 The C7 alkylenes and C7 alkenylenes are selected, and each of them contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 The C8 alkylenes and C8 alkenylenes are selected, and each of them contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 It is -CH2CHCH(CH2)4-. In some embodiments, L 2 is one or more R 11b It is a 6- to 8-membered heteroalkylene that is optionally substituted with L. In some embodiments, 2 is one or more R 11b It is a 6-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 is one or more R 11b It is a 7-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 is one or more R 11b It is an 8-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 It is an 8-membered heteroalkylene, and the heteroalkylene contains one oxygen atom. In some embodiments, L 2 is, -(CH2) 2-5 O(CH2) 0-5 - and for example, L 2 is, -(CH2) 2-5 O(CH2) 2-5 - is. In some embodiments, L 2is -(CH2)4O(CH2)3-. In some embodiments, R 11b In each appearance, halogen, oxo, and C are present. 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 The alkyl)-OH and -OH are selected independently. In some embodiments, R 11b In each occurrence, R is independently selected from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, -CH3, -CH2OH, -CH2F, -CHF2, and -CF3 are independently selected, or two R 11b They combine to equal O or C 3-6 A cycloalkyl group, for example, cyclopropyl, is formed. In some embodiments, R 11b In each occurrence, -CH3, -CH2OH, -CH2F, -CHF2, and -CF3 are independently selected, or two R 11b They combine, C 3-6 A cycloalkyl group, for example, cyclopropyl, is formed. In some embodiments, R 11b In each occurrence, is independently selected from -CH3, -F, -CN, and -OH. In some embodiments, L 2 is -C(O)N(R 14 )- or -N(R 14 )C(O)- contains. In some embodiments, L 2 It contains -O-. In some embodiments, L 2 It is substituted with at least one -CH3, -CH2OH, -CH2F, -CHF2, or -CF3, or two substituents are bonded to form a cyclopropyl. In some embodiments, L 2 is replaced by at least one -CH3, -F, -CN, or -OH. In some embodiments, L 2 This is a non-substitution.

[0163] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 is, -(C 1-5 Alkylene)-C(O)N(R) 14 )-(C 1-5 Alkylene)-, for example, -(C 1-5 Alkylene)-C(O)N(CH3)-(C 1-5 Alkilen)-or-(C 1-5 Alkylene)-C(O)NH-(C 1-5 Alkylene)- and C -1-5 Alkylene is one or more R 11b It is optionally replaced by L. In some embodiments, 2 is, -(C 1-2 Alkylene)-C(O)N(R) 14 )-(C 3-4 Alkylene)-, for example-(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkilen)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)- and C -1-2 Alkylene and C 3-4 Each alkylene independently has one or more R 11b It is optionally replaced by R. In some embodiments, 11b In each occurrence, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 The alkyl)-OH and -OH are selected independently. In some embodiments, R 11b In each occurrence, is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, -CH3, -CH2OH, -CH2F, -CHF2, and -CF3 are independently selected, or two R 11b They combine, C3-6 A cycloalkyl group, for example, cyclopropyl, is formed. In some embodiments, R 11b In each occurrence, is independently selected from -CH3, -F, -CN, and -OH. In some embodiments, L 2 It is substituted with at least one -CH3, -F, -CN, or -OH group.

[0164] In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH2-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkylene)-CH(R 11b )-,-CH2-(C 3-10 Alkylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(C 3-10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkenylene)-C(R 11b )(R 11b )-,-CH2-(C 3-10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkenylene)-CH(R 11b )-,-CH2-(C 3-10 Alkenylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-CH(R 11b )-,-CH2-(3-10 member heteroalkylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkenylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH2-(C 3-10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkylene)-CH(R 11b )-, and -CH2-(C 3-10 Alkylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3-10Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkenylene)-C(R 11b )(R 11b )-,-CH2-(C 3-10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3-10 Alkenylene)-CH(R 11b )-, and -CH2-(C 3-10 Alkenylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )-(R 11b )-,-CH2-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkelene)-CH(R 11b)- Selected from any C in this paragraph. 3-10 Alkilen, C 3-10 Alkenylenes, 3-10 membered heteroalkylenes, or 3-10 membered heteroalkenylenes are one or more R 11b It may be optionally replaced by R. In some embodiments, 11b In each appearance, halogen, oxo, and C are present. 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 The alkyl)-OH and -OH are selected independently. In some embodiments, R 11b In each occurrence, is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, -CH3, -CH2OH, -CH2F, -CHF2, and -CF3 are independently selected, or two R 11b They combine to equal O or C 3-6 It forms a cycloalkyl group, such as cyclopropyl.

[0165] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1-10 Alkilen, C 2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by either D being absent or C 3-12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which has one or more R 11d It is optionally replaced by L 4 C 1-10 Alkilen, C2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally substituted. As mentioned above, the alkenylene group and the alkynylene group each contain one or more carbon-carbon double or triple bonds (i.e., for example, C 2-10 Alkenylene, C 2-10 Alkinylene, C 2-8 Alkenylene, C 2-8 Alkinylene, C 5-25 Alkenylene, C 5-25 Alkinylene, C 6-15 Alkenylene, C 6-15 Alkinylene, C 5-10 Alkenylene and C 5-10 (Like alkynylenes, which contain two or more carbon atoms). Similarly, heteroalkenylene groups contain one or more carbon-carbon double bonds (i.e., two or more carbon atoms and one or more heteroatoms, such as 3-10 membered heteroalkenylenes, 3-8 membered heteroalkenylenes, 5-25 membered heteroalkenylenes, 6-15 membered heteroalkenylenes, and 5-10 membered heteroalkenylenes. In some embodiments, L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1-10 Alkilen, C 2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by C 3-12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which has one or more R 11d It is optionally replaced by L 4 L is absent. In some embodiments, L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1-8Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by either D being absent or C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 11b In each occurrence, halogen, oxo, and C are present. 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 The alkyl)-OH and -OH are selected independently. In some embodiments, R 11b In each occurrence, is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11bIn each occurrence, -CH3, -CH2OH, -CH2F, -CHF2, and -CF3 are independently selected, or two R 11b They combine to equal O or C 3-6 It forms a cycloalkyl, for example, cyclopropyl. In some embodiments, D is selected from phenyl, and 5-8 membered heteroaryls, for example, triazole and imidazole. In some embodiments, D is unsubstituted. In some embodiments, D is one or more R 11d For example, 1, 2, or 3 R 11d It has been replaced with.

[0166] In some embodiments, for the compound of formula (I), L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 It forms a covalent bond with one of them. For example, L 2 is, W 3 It may also be covalently bonded, in which case R 3b or R 3 As shown in equation (IA), L 2 This is a combination with L. In some embodiments, L 2 is, W 4 Covalently bonded to, in this case, R 4b or R 4 As shown in equation (IB), L 2 This is a combination with L. In some embodiments, L 2 is, W 5 Covalently bonded to, in this case, R 5b or R 5 As shown in equation (IC), L 2 This is a combination with L. In some embodiments, L 2 is, W6 Covalently bonded to, in this case, R 6b or R 6 As shown in formula (ID), L 2 This is a combination with L. In some embodiments, L 2 is, W 7 Covalently bonded to, in this case, R 7b or R 7 As shown in formula (IE), L 2 It is a combination of the two.

[0167] In some embodiments, for compounds of formula (I), (IA), (IB), (I-1), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , and -N(R 22 )(R 23 ) is optionally replaced by one, two, or three bases independently selected from, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with 1, 2, or 3 groups independently selected.

[0168] In some embodiments, for compounds of formula (I), (IA), (IB), (I-1), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 20 In each occurrence, halogen, oxo, =NR 22 ,-CN,C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25, -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)(NR 22 )R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, and =NR 22 ,-CN,C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , and -N(R 22 )(R 23 It is optionally substituted with one, two, or three bases selected independently of ).

[0169] In some embodiments, for compounds of formula (I), (IA), (IB), (I-1), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 20 In each occurrence, halogen, oxo, =NH, -CN, -NO2, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Independently selected from carbon rings, 3-10 membered heterocycles, -CH2-(3-10 membered heterocycles), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, C 1-6Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, -CH2- (3- to 10-membered heterocycles) are halogens, oxo compounds, =NH, -CN, -NO2, -CH3, -CH2CH3, -CH(CH -3 It is optionally substituted with one, two, or three groups independently selected from -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3.

[0170] In some embodiments, for the compound of formula (I-B1), R 5b It is -CH3, and R 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 is hydrogen. In some embodiments, for the compound of formula (I-B2), R 5 is hydrogen, and R 6 R is selected from hydrogen and -OCH3. 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 It is hydrogen.

[0171] In some embodiments, for the compound of formula (I-C1), R 3 is hydrogen or -CH3, and R 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 is hydrogen. In some embodiments, for the compound of formula (I-C2), R 3b It is -CH3, and R 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 is hydrogen. In some embodiments, for the compound of formula (I-C3), R 3 is hydrogen or -CH3, and R 6 R is selected from hydrogen and -OCH3.7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 It is hydrogen.

[0172] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 It is -CH3, [ka] These are selected from phenyl and 5-7 member heteroaryl compounds, each of which has one or more R 11 It is optionally replaced by L 1 is bond and C 1-3 Selected from haloalkylenes, [ka] is selected from absent, phenyl, and 4- to 8-membered heterocycles, wherein the phenyl and 4- to 8-membered heterocycles are one or more R 11a It is optionally replaced by L 2 However, C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 11If present, it is fluorine, and R 11a If present, it is -CH3, and R 11b If present, halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 Selected from alkyl)-OH and -OH.

[0173] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] is one or more R 11a Replaced by an optional substitution [ka] And L 2 C 6-8 Alkilen, C 6-8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] And L1 C 1-2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is one or more R 11b It is a 6- to 8-membered heteroalkylene that is optionally substituted with R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] is one or more R 11a Replaced by an optional substitution [ka] And L 2 C 6-8 Alkylene and C 6-8 Selected from alkenylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] And L 1 C 1-2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is one or more R 11b C is optionally replaced by 6-8 It is an alkenylene. 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] is one or more R 11a Replaced by an optional substitution [ka] And L 2 is, -(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkilen)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)- and C -1-2 Alkylene and C 3-4 Each alkylene independently has one or more R 11b It is optionally replaced by R. In some embodiments, 11a If present, it is -CH3, and R 11b If present, halogen, -CN, oxo, C 1-3 Alkyl, C 1-3 Haloalkyl, (C 1-3 Selected from alkyl)-OH and -OH.

[0174] In some embodiments, for compounds of formula (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), or (I-E1), R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] teeth, [ka] And L 2 C 6-8 Alkilen, C 6-8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] teeth, [ka] And L 2 C 6-8 Alkylene and C 6-8Selected from alkenylenes, each of which contains one or more R 11b It is optionally replaced by R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1-2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is, -(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkilen)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)- and C -1-2 Alkylene and C 3-4 Each alkylene independently has one or more R 11b It is optionally replaced by R. In some embodiments, 11b If present, halogen, -CN, oxo, C 1-3 Alkyl, C 1-3 Haloalkyl, (C 1-3 Selected from alkyl)-OH and -OH.

[0175] In some embodiments, the compound of formula (I) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or R 11 And R 51 It is either hydrogen or a halogen.

[0176] In some embodiments, the compound of formula (I) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (IA) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (IB) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (IC) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (IC) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (ID) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, the compound of formula (IE) is the compound of the following formula: [ka] And in the formula, R 50 is hydrogen or fluoro. In some embodiments, L 1 C 1-3Haloalkylenes, for example, C 1-2 Haloalkylene or C 1-2 It is a fluoroalkylene. In some embodiments, L 2 C 6-8 Alkilen, C 6-8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 C 6-8 Alkylene and C 6-8 Selected from alkenylenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, 2 is, -(C 1-2 Alkylene)-C(O)N(CH3)-(C 3-4 Alkilen)-or-(C 1-2 Alkylene)-C(O)NH-(C 3-4 Alkylene)- and C -1-2 Alkylene and C 3-4 Each alkylene independently has one or more R 11b It is optionally replaced by R. In some embodiments, 11b If present, halogen, -CN, C 1-3 Alkyl, C 1-3 Haloalkyl, (C 1-3 Selected from alkyl)-OH and -OH. In some embodiments, R 50 is hydrogen. In some embodiments, R 50 It is fluoro.

[0177] In certain embodiments, this disclosure relates to compounds of formula (I-C1): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] Selected from, [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by, R 1 It is -CH3, R 3 is hydrogen or -CH3, R 7 teeth, [ka] Selected from, R 8 It is hydrogen, R 11 It is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 Selected from alkyl)-OH and -OH.

[0178] In certain embodiments, this disclosure relates to compounds of formula (I-C1): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] Selected from, [ka] It is selected from azetidine, pyrrolidine, and piperidine. L 1 It is selected from -CF2-, -CF2CH2-, and -CF2CH2CH2-, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkenylenes, R 1 It is -CH3, R 3 is hydrogen or -CH3, R 7 teeth, [ka] Selected from, R 8 It is hydrogen.

[0179] In certain embodiments, this disclosure relates to compounds of formula (I-C1): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] Selected from, [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. L1 C 1-3 It is a haloalkylene, L 2 is one or more R 11b C is optionally replaced by 5-10 It is alkenylene, R 1 It is -CH3, R 3 It is -CH3, R 7 teeth, [ka] Selected from, R 8 It is hydrogen, R 11 It is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 Selected from alkyl)-OH and -OH.

[0180] In certain embodiments, this disclosure relates to compounds of formula (I-C1): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] Selected from, [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. L 1 C 1-3 It is a haloalkylene, L 2 is one or more R 11b Selected from 5-10 member heteroalkylenes that have been optionally substituted, R 1 It is -CH3, R 3 is hydrogen or -CH3, R 7 teeth, [ka] Selected from, R 8 It is hydrogen, R 11 It is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1-6 Alkyl, C 1-6 Haloalkyl, (C 1-6 Selected from alkyl)-OH and -OH.

[0181] In certain embodiments, this disclosure relates to compounds of formula (I): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] These are selected from phenyl and 5-7 member heteroaryl compounds, each of which has one or more R 11 It is optionally replaced by, [ka] is either absent or selected from phenyl and 4- to 8-membered heterocycles, each of which has one or more R 11a It is optionally replaced by, L 1 is bond and C 1-3 Selected from haloalkylenes, L 2 C5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, L 3 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, D is C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by, L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, W 2 N is, W 3 N(R) 3b ), N, C(R 3 ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected, W 5N(R) 5b ), N, and C(R 5 ) are selected from, W 6 C(R 6 ) and C(O) are selected, W 7 C(R 7 ) and W 8 C(R 8 ) and W 9 and W 10 Each of them is C, R 1 It is -CH3, R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a Each is independently selected from hydrogen and -CH3, R 3 , R 4 , R 5 , and R 6 Each of them is L 2 Bonding with hydrogen, halogen, -CN, C 1-3 Alkyl, C 1-3 Independently selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2, R 7 L 2 The combination with C 1-6 Alkyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms.20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, and C 1-3 Selected independently of alkyl, R 11 , R 11a , and R 11d In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0182] In certain embodiments, this disclosure relates to compounds of formula (III): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is one or more R 11a Selected from 3- to 8-membered complex rings that are arbitrarily substituted, L 1 is a bond, C 1-6 Alkylene and C 1-6 Selected from haloalkylenes, L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, L 3 C 1-10 Alkilen, C 2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by, D is absent, or C 3-12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which has one or more R 11d It is optionally replaced by, L 4 C 1-10 Alkilen, C2-10 Alkenylene, C 2-10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which contains one or more R 11b It is optionally replaced by, W 3 N(R) 3b ) and N are selected, W 4 C(R 4 ) and C(O) are selected, or W 3 C(R 3 ) and C(O) are selected, W 4 N(R) 4b ) and N are selected, W 5 N(R) 5b ), N, and C(R 5 ) are selected from, W 6 N, C(R 6 ) and C(O) are selected, W 7 N, C(R 7 ) and C(O) are selected, R 50 is hydrogen or halogen, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11a and R 11d In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14)C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0183] In certain embodiments, this disclosure relates to compounds of formula (III): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is one or more R 11a Selected from 3- to 8-membered complex rings that are arbitrarily substituted, L 1 is a bond, C 1-6 Alkylene and C 1-6 Selected from haloalkylenes, L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, W 3 N(R) 3b ) and N are selected, W 4 C(R 4 ) and C(O) are selected, or W 3 C(R 3 ) and C(O) are selected, W4 N(R) 4b ) and N are selected, W 5 N(R) 5b ), N, and C(R 5 ) are selected from, W 6 N, C(R 6 ) and C(O) are selected, W 7 N, C(R 7 ) and C(O) are selected, R 50 is hydrogen or halogen, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11a In each occurrence, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12)S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0184] In some embodiments, the compound of formula (III) is the compound of the following formula: [ka] That is the case.

[0185] In some embodiments, the compound of formula (III) is the compound of the following formula: [ka] That is the case.

[0186] In some embodiments, for the compound of formula (III), [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which contains one or more R 11a It is optionally replaced by, [ka] teeth, [ka] And each of them is one or more R 11a It is optionally replaced by, [ka] is one or more R 11a Replaced by an optional substitution [ka] In some embodiments, L 1 C 1-3 It is a haloalkylene. 2 C 5-10 Selected from alkylene, C 5-10 Alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, L 3 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced, and D becomes C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is being replaced by an arbitrary choice.

[0187] In certain embodiments, this disclosure relates to compounds of the following formulas: [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 It is covalently bonded to one of the following, or L 2 is, -L 3 -DL4 - and L 4 However, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, L 3 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, D is C 3-10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by, L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, W 2 N(R) 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 N(R) 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 N(R) 5b ), N, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 6N(R) 6b ), N, C(R 6 ), C(R 6 )(R 6a ), and C(O) are selected, W 7 N(R) 7b ), N, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, W 8 N(R) 8b ), N, C(R 8 ), C(R 8 )(R 8a ), and C(O) are selected, W 9 N, C(R 9 ), and C are selected, W 10 N, C(R 10 ), and C are selected, R 2 , R 2a , R 3a , R 4a , R 5a , R 6a , R 7a , R 8 , and R 8a These are hydrogen, halogen, -CN, and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15, -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 2b and R 8b These are hydrogen, -CN, and C respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12)(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 The carbon ring and the 3- to 10-membered heterocycle independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , R 5b , R 6b , and R 7b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 9 and R 10 These are hydrogen and C, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 A carbon ring is independently selected from a 3- to 10-membered heterocycle and a -CH2- (3- to 10-membered heterocycle), and each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 The carbon ring, 3- to 10-membered heterocycle, and -CH2- (3- to 10-membered heterocycle) independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11d In each occurrence, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15, -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25, -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0188] In certain embodiments, this disclosure relates to compounds of formula (II-B) or (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is absent, or one or more R 11a It is a 4- to 8-membered complex ring that is arbitrarily substituted with, L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is either optionally replaced by L 2 However, -L 3 -DL 4 -and, L 3 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, D is C 3-10Selected from carbon rings and 3- to 10-membered heterocycles, each of which contains one or more R 11d It is optionally replaced by, L 4 C 1-8 Alkilen, C 2-8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which contains one or more R 11b It is optionally replaced by, R 3 and R 8 Each is independently selected from hydrogen and -CH3, R 7 C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 5b is hydrogen and C 1-3 Selected from alkyl groups, R 50 It is selected from hydrogen and halogens. R 11a and R 11d In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24)S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, hydrogen and C 1-6 Selected independently of alkyl, R 24 In each appearance, hydrogen and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with 1, 2, or 3 groups independently selected.

[0189] In some embodiments, this disclosure relates to compounds of formula (II-B) or (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is absent, or one or more R 11a It is a 4- to 8-membered complex ring that is arbitrarily substituted with, L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by, R 3 , R 5b , and R 8 Each is independently selected from hydrogen and -CH3, R 7 C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 50 It is selected from hydrogen and halogens. R 11a In each occurrence, halogen, C 1-3 Alkyl, and C 1-3 Selected independently from haloalkyl groups, R 11b In each occurrence, halogen, oxo, -CN, and C appear.1-3 Selected independently from alkyl and -OH groups, R 20 In each appearance, halogen, oxo, -CN, and C are present. 1-6 It is selected independently of alkyl.

[0190] In some embodiments, this disclosure relates to a compound of formula (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is absent, or one or more R 11a It is a 4- to 8-membered complex ring that is arbitrarily substituted with, L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by, R 3 It is hydrogen, R 8 It is selected from hydrogen and -CH3, R 7 teeth, [ka] Selected from, R 50 It is selected from hydrogen and halogens. R 11a In each occurrence, halogen, C 1-3 Alkyl, and C 1-3 Selected independently from haloalkyl groups, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-3Selected independently from alkyl and -OH groups, R 20 In each appearance, halogen, oxo, -CN, and C are present. 1-6 It is selected independently of alkyl.

[0191] In some embodiments, this disclosure relates to a compound of formula (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] is one or more R 11a It is a 4- to 8-membered complex ring that is arbitrarily substituted with, L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b It is optionally replaced by, R 3 It is selected from hydrogen and -CH3, R 8 It is selected from hydrogen and -CH3, R 7 teeth, [ka] Selected from, R 50 It is selected from hydrogen and halogens. R 11a In each occurrence, halogen, C 1-3 Alkyl, and C 1-3 Selected independently from haloalkyl groups, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-3It is independently selected from alkyl and -OH groups.

[0192] In some embodiments, this disclosure relates to a compound of formula (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] It is a 4-6 member complex ring, L 1 C 1-3 It is a haloalkylene, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes and 5-10 membered heteroalkylenes, R 3 It is selected from hydrogen and -CH3, R 8 It is hydrogen, R 7 teeth, [ka] Selected from, R 50 The element is selected from hydrogen and halogens.

[0193] In some embodiments, this disclosure relates to a compound of formula (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] And, L 1 It is -CF2CH2-, L 2 These are 5-10 member heteroalkylenes, and each heteroalkylene contains one oxygen atom. R 3 It is selected from hydrogen and -CH3, R 8 It is hydrogen, R 7 teeth, [ka] Selected from, R 50 The element is selected from hydrogen and halogens.

[0194] In some embodiments, this disclosure relates to a compound of formula (II-C): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] teeth, [ka] And, L 1 It is -CF2-, L 2 C 5-10 Selected from alkenylenes, R 3 It is selected from hydrogen and -CH3, R 8 It is hydrogen, R 7 teeth, [ka] Selected from, R 50 The element is selected from hydrogen and halogens.

[0195] In some embodiments, the compound of formula (II-B) is the compound of the following formula: [ka] In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R 50 R is selected from hydrogen and fluoro. In some embodiments, 5b It is -CH3, and R 8 is hydrogen, and R 50 is hydrogen. In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R 50 is fluoro. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R 50 is hydrogen, and R 7 teeth, [ka] Selected from. In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R 50 is fluoro, and R 7 teeth, [ka] Selected from. In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R 50 R is selected from hydrogen and fluoro, 7 teeth, [ka] In some embodiments, R 5b It is -CH3, and R 8 is hydrogen, and R50 is selected from hydrogen and fluoro, R 7 is

Chemical Formula

Chemical Formula

[0196] In some embodiments, the compound of formula (II-C) is a compound of the following formula:

Chemical Formula

Chemical Formula

[0197] Embodiments disclosed herein that refer to compounds of formulas (I), (IA), (IB), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), and / or (I-E1) are also intended to apply to compounds of formulas (I-1), (II-B), (II-C), and (III) unless otherwise explicitly indicated (for example, embodiments that refer to variables not present in compounds of formulas (I-1), (II-B), (II-C), or (III), e.g., R 1 (Only referring to this.)

[0198] In some embodiments, the compound of formula (I) is the compound of the following formula: [ka] or its salt or solvate.

[0199] In certain embodiments, this disclosure relates to compounds of formula (I-1): [ka] or provides a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] C 5-7 Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, [ka] is absent, or C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains one or more R 11a It is optionally replaced by, L 1 is a bond, C 1-6 Alkylene and C 1-6Selected from haloalkylenes, L 2 C 5-25 Alkilen, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, W 3 N(R) 3b ), N, C(R 3 ), and C(O) are selected, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected, W 5 N(R) 5b ), N, and C(R 5 ) are selected from, W 6 C(R 6 ) and C(O) are selected, W 7 C(R 7 ) and R 1 is one or more R 11c C is optionally replaced by 1-3 It is alkyl, R 8 Hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 The carbon ring and the 3- to 10-membered heterocycle each independently contain 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11 and R 11a In each occurrence, halogen, -CN, and C are used, respectively. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C appear. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11c In each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) were selected independently of, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom they bond to, form 1, 2, or 3 R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following elements. R 14 In each appearance, hydrogen and C 1-6 Alkyl, and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R groups. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected independently from C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH2-(C 3-10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 They are optionally substituted with 1, 2, or 3 groups independently selected from carbon rings and 3- to 10-membered heterocycles. [ka] This indicates a single or double bond where all valencies are satisfied.

[0200] In some embodiments, the compound of formula (I-1) is the compound of formula (I-B1) or (I-B2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0201] In some embodiments, the compound of formula (I-1) is the compound of the following formulas (I-C1), (I-C2), or (I-C3): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0202] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), R 1 is -CH3. In some embodiments, for compounds of formula (I-1), (I-C1), or (I-C3), R 3 These are hydrogen, -CN, and -OR 12Selected from , and -CH3. In some embodiments, for compounds of formula (I-1), (I-B2), or (I-C3), R 6 is hydrogen, -OR 12 , and 1, 2, or 3 R 20 C is optionally replaced by 1-6 Selected from alkyl, R 12 C 1-6 Selected from alkyl. In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), R 8 It is hydrogen.

[0203] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), R 7 C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 member heterocycloalkyl, and -N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Cycloalkyls and 3- to 10-membered heterocycloalkyls have 1, 2, or 3 R 20 It is optionally replaced by R. In some embodiments, 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from.

[0204] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), [ka] These are selected from phenyl and 5-7 member heteroaryl compounds, each containing one or more R 11 It is optionally replaced by, [ka] teeth, [ka] Selected from. In some embodiments, R 11 The component is selected independently of fluorine and -CH3.

[0205] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), L 1 C 1-3 It is a haloalkylene. 1 The following are selected: -CF2-, -CF2CH2-, and -CF2CH2CH2-.

[0206] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), [ka] R is either absent or selected from phenyl and 4- to 8-membered heterocycles, in which case phenyl and 4- to 8-membered heterocycles are one or more R 11a It is optionally replaced by, [ka] These are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups.

[0207] In some embodiments, for compounds of formula (I-1), (I-B1), (I-B2), (I-C1), (I-C2), or (I-C3), L 2 C6-15 Alkilen, C 6-15 Alkenylene, C 6-15 Selected from alkylylenes, 6-15 member heteroalkylenes, and 6-15 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L. In some embodiments, L 2 C 5-10 Alkilen, C 5-10 Selected from alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkenylenes, each of which contains one or more R 11b These are optionally substituted. In some embodiments, the alkenylenes and heteroalkenylenes contain one carbon-carbon double bond. In some embodiments, the heteroalkylenes and heteroalkenylenes contain at least one oxygen or nitrogen atom.

[0208] In some embodiments, for compounds of formula (I-1), (I-B1), or (I-B2), R 5 is hydrogen, and R 5b It is -CH3, and R 6 R is selected from hydrogen and -OCH3. 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 It is hydrogen.

[0209] In some embodiments, for compounds of formula (I-1), (I-C1), (I-C2), or (I-C3), R 3is hydrogen or -CH3, and R 3b It is -CH3, and R 6 R is selected from hydrogen and -OCH3. 7 C 1-6 Alkyl, C 3-10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by R 8 It is hydrogen.

[0210] Examples of small molecule SOS1 inhibitors suitable for use in the methods of this disclosure, including synergistic inhibition of EGFR-mediated cancer cell proliferation in combination with osimertinib, include compounds of formula (I), formula (IA), formula (IB), formula (I-1) (including compound A), formula (I-B1), formula (I-B2), formula (IC), formula (I-C1), formula (I-C2), formula (I-C3), formula (ID), formula (I-D1), formula (I-D2), formula (IE), formula (I-E1), formula (II-B), formula (II-C), and formula (III). Examples of small molecule SOS1 inhibitors, but not limited to, include compounds selected from Table 1 (including compound A) or their salts or solvates.

[0211] In some embodiments, the compounds disclosed herein, such as compounds of formula (I), (IA), (IB), (I-1), (I-B1), (I-B2), (IC), (I-C1), (I-C2), (I-C3), (ID), (I-D1), (I-D2), (IE), (I-E1), (II-B), (II-C), or (III), are provided as substantially pure stereoisomers. In some embodiments, the stereoisomers are provided with at least 80% enantiomer excess, for example, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.9% enantiomer excess.

[0212] In some embodiments, the compounds described herein exist as pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.

[0213] In some embodiments, the compounds described herein have acidic or basic groups and therefore react with a number of inorganic or organic bases, or inorganic or organic acids, to form pharmaceutically acceptable salts. In some embodiments, such salts are prepared in situ during the final isolation and purification of the compounds described herein, or by reacting the purified compound in its free form separately with a suitable acid or base and isolating the salts thus formed.

[0214] In some embodiments, the compounds described herein exist as solvates. In some embodiments, there are methods for treating diseases by administering such solvates. Furthermore, this specification describes methods for treating diseases by administering such solvates as pharmaceutical compositions.

[0215] Solvates contain a stoichiometric or non-stoichiometric amount of solvent and, in some embodiments, are formed during a crystallization process using a pharmaceutically acceptable solvent such as water or ethanol. If the solvent is water, a hydrate is formed; if the solvent is alcohol, an alcoholate is formed. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. As just one example, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous / organic solvent mixture using an organic solvent including, but not limited to, dioxane, tetrahydrofuran, or MeOH. In addition, the compounds provided herein exist in both solvated and unsolvated forms. Generally, the solvated form is considered equivalent to the unsolvated form for the purposes of the compounds and methods provided herein.

[0216] The chemical substances described herein can be synthesized according to one or more exemplary schemes herein and / or techniques known in the art. The substances used herein are commercially available or prepared by synthetic methods commonly known in the art. These schemes are used for illustrative purposes and are not limited to the compounds listed in the examples or compounds with any particular substituents. Various steps are described and illustrated in Schemes 1 to 8, but in some examples, the steps may be carried out in an order different from that shown in Schemes 1 to 8. Various modifications to these synthetic reaction schemes may be made and will be suggested to those skilled in the art who have referred to this disclosure. The numbering or R group in each scheme typically has the same meaning as defined elsewhere herein, unless otherwise indicated.

[0217] Unless otherwise specified, the reactions described herein are carried out at atmospheric pressure and generally within a temperature range of -10°C to 200°C. Furthermore, unless otherwise specified, reaction times and conditions are approximate values, intended to be carried out over a period of about 1 to 24 hours at near atmospheric pressure within a temperature range of about -10°C to about 110°C, with the reaction left to react overnight for an average period of about 16 hours.

[0218] In general, the compounds of this disclosure can be prepared by the following reaction scheme. Scheme 1 [ka]

[0219] In some embodiments, compounds of formula 1e can be prepared according to scheme 1. For example, heteroarylamine 1b can be formed from chloride 1a via a nucleophilic aromatic substitution reaction. Lactam substitution can proceed under basic conditions to obtain diene 1c, which can then be formed into a macrocyclic compound 1d via a cross-metathesis reaction such as a Grubbs cross-metathesis reaction. Optionally, 1d can be subjected to one or more subsequent reactions, such as a hydrogenation reaction, to provide a compound of formula 1e. Scheme 2 [ka]

[0220] Similarly, in some embodiments, compounds of formula 2e can be prepared according to scheme 2. For example, heteroarylamine 2b can be formed from chloride 2a via a nucleophilic aromatic substitution reaction. Lactam substitution can proceed under basic conditions to obtain diene 2c, which can then be used to form a macrocyclic compound 2d via a cross-metathesis reaction such as a Grubbs cross-metathesis reaction. Optionally, 2d can be subjected to one or more subsequent reactions, such as a hydrogenation reaction, to provide a compound of formula 2e. Scheme 3 [ka]

[0221] In some embodiments, compounds of formula 3e can be prepared according to scheme 3. For example, heteroarylamine 3b can be formed from chloride 3a via a substitution reaction. By lactam substitution, a protected amine 3c can be obtained. Hydrolysis of the ester can form carboxylic acid 3d, which can then be deprotected and subjected to peptide coupling reactions to obtain the macrocyclic compound of formula 3e. Scheme 4 [ka]

[0222] Similarly, in some embodiments, compounds of formula 4e can be prepared according to scheme 4. For example, heteroarylamine 4b can be formed from chloride 4a via a substitution reaction. By lactam substitution, a protected amine 4c can be obtained. Hydrolysis of the ester can form a carboxylic acid 4d, which can then be deprotected and undergo a peptide coupling reaction to obtain the macrocyclic compound of formula 4e. Scheme 5 [ka]

[0223] In some embodiments, the compounds of formula 5g can be prepared according to scheme 5. For example, heteroarylamine 3c can be formed by coupling chloride 5a with amine 5b. Oxidation of the alcohol can yield aldehyde 5d, which can then be substituted with phenol to obtain 5e. Removal of the amine protecting group yields 5f, which can then be reductively aminated to form the macrocyclic compound of formula 5g. Scheme 6 [ka]

[0224] In some embodiments, compounds of formula 6f can be prepared according to scheme 6. For example, heteroarylamine 6c can be formed by coupling chloride 1a...

Claims

1. A method for reducing the proliferation of cancer cells containing an epidermal growth factor receptor (EGFR) exon 20 insertion, comprising administering (a) an SOS1 inhibitor and (b) osimertinib to cells, wherein (a) is administered before, simultaneously with, or after the administration of (b).

2. The method according to claim 1, wherein the cancer cells are non-small cell lung cancer cells.

3. A method for downregulating EGFR signaling output in multiple non-small cell lung cancer cells, (i) Evaluate the EGFR mutation status in biological samples containing nucleic acids derived from the target, (ii) If an EGFR exon 20 insertion is detected in the sample, a method comprising administering (a) an effective dose of an SOS1 inhibitor and (b) an effective dose of osimertinib, wherein (a) is administered before, simultaneously with, or after the administration of (b).

4. A method for treating cancer in a subject, comprising administering (a) an SOS1 inhibitor and (b) a MET inhibitor to the subject, wherein (a) is administered before, simultaneously with, or after the administration of (b).

5. The method according to claim 4, wherein the cancer is an EGFR-mediated cancer.

6. The method according to claim 4 or 5, wherein the cancer exhibits MET amplification.

7. The method according to any one of claims 4 to 6, wherein the MET inhibitor is savolitinib.

8. (c) The method according to any one of claims 4 to 7, further comprising administering an additional drug or additional therapy.

9. The method according to claim 8, wherein the additional agent is an EGFR inhibitor.

10. The method according to claim 9, wherein the EGFR inhibitor is selected from gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, poziotinib, mobosertinib, diparereltinib, sambosertinib, BAY-2927088, BLU-451, BLU-945, STX-721, and zolifertinib.

11. The method according to claim 9, wherein the EGFR inhibitor is osimertinib.

12. The method according to claim 8, wherein the additional therapy is selected from surgery, cell therapy, chemotherapy, and radiation.

13. The method according to any one of claims 1 to 12, wherein the administrations of (a) and (b) synergistically reduce the proliferation of cancer cells by a synergistic effect value of at least 0.1, as confirmed by the Bliss independence criterion.

14. A method for treating EGFR-mediated cancer in a subject, comprising administering to the subject (a) an SOS1 inhibitor and (b) osimertinib, wherein (a) is administered before, simultaneously with, or after the administration of (b), and the administrations of (a) and (b) synergistically reduce the proliferation of cancer cells with a synergistic effect value of at least 0.1, as confirmed by the Bliss independence criterion.

15. The aforementioned synergistic value was confirmed by the Bliss independence criterion according to the following formula: Y AB,O -Y AB,P During the ceremony, Y AB,O This is the percentage of cancer cell proliferation inhibition observed by the application of (a) and (b), including dose A(a) and dose B(b). Y AB,P is the predicted cancer cell proliferation inhibition rate by the application of (a) at dose A and (b) at dose B, wherein Y AB,P = Y A + Y B - Y A Y B , Y A This is the percentage of cancer cell proliferation inhibition observed by (a) alone at dose A, Y B This is the percentage of cancer cell proliferation inhibition observed by (b) alone at dose B, and Y A Y B Y A and Y B The method according to claim 13 or 14, wherein the product of the two.

16. The method according to any one of claims 13 to 15, wherein the synergistic effect value is at least 0.

4.

17. The method according to any one of claims 13 to 15, wherein the synergistic value is at least 1.

18. The method according to any one of claims 13 to 15, wherein the synergistic value is at least 5.

19. The SOS1 inhibitor is a compound of formula (I-1): 【Chemistry 1】 or a pharmaceutically acceptable salt or solvate thereof, in the formula, 【Chemistry 2】 C 5-7 Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, 【Transformation 3】 is absent, or C 3-8 Selected from carbon rings and 3- to 8-membered heterocycles, each of which contains one or more R 11a It is optionally replaced by, L 1 C 1-6 Alkylene and C 1-6 Selected from haloalkylenes, L 2 C 5-25 Alkylene, C 5-25 Alkenylene, C 5-25 Selected from alkylylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkenes, each of which contains one or more R 11b It is optionally replaced by L 2 is, W 3 , W 4 , W 5 , W 6 , or W 7 Covalently bonded to one of them, W 3 N(R) 3b ), N, C (R 3 Selected from C(O), W 4 N(R) 4b ), N, C (R 4 Selected from C(O), W 5 N(R) 5b ), N, and C (R 5 ) are selected from, W 6 is C(R 6 ) and C(O) are selected, W 7 is C(R 7 ) and R 1 is one or more R 11c C is optionally replaced by 1-3 It is alkyl, R 8 is hydrogen, halogen, -CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 carbocycle, 3- to 10-membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH 2 C(O)N(R 12 )(R 13 ), -CH 2 N(R 14 )C(O)R 15 , -CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R 12 )(R 13 ), and C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 The carbon ring and the 3- to 10-membered heterocycle each independently contain 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 3 , R 4 , R 5 , R 6 , and R 7 Each is L 2 Bonding with hydrogen, halogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 3b , R 4b , and R 5b Each is L 2 Bonding with hydrogen, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected independently from each C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 The carbon rings and 3- to 10-membered heterocycles independently have 1, 2, or 3 R groups. 20 It is optionally replaced by, R 11 and R 11a In each occurrence, halogen, -CN, and C are respectively present. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11b In each occurrence, halogen, oxo, -CN, and C are present. 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected independently of C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 11c In each occurrence, halogen, -OR 12 , and -N(R 12 ) (Caution 13 ) were selected independently of, R 12 In each appearance, hydrogen and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 13 In each appearance, hydrogen and C 1-6 Alkyl and C 1-6 Independently selected from haloalkyls, or R 12 and R 13 These, together with the nitrogen atom to which they bond, form 1, 2, or 3 R atoms. 20 They form 3- to 10-membered heterocycles by any optional substitution, R 14 In each appearance, hydrogen and C 1-6 Alkyl and C 1-6 Selected independently from haloalkyl groups, R 15 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles have 1, 2, or 3 R atoms. 20 It is optionally replaced by, R 17 and R 17a In each occurrence, C 1-6 Alkyl and C 3-6 Selected independently from cycloalkyl, C 1-6 Alkyl and C 3-6 Cycloalkyl groups have 1, 2, or 3 R atoms. 20 It is either optionally replaced by R 17 and R 17a These, together with the phosphorus atoms to which they are bonded, form a 3- to 10-membered heterocycle. R 20 In each occurrence, halogen, oxo, =NH, -CN, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH 2 - (C 3-10 Carbon rings), 3- to 10-membered heterocycles, -CH 2 - (3- to 10-membered complex ring), - OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), -OCH 2 C(O)OR 22 , and -OC(O)R 25 Selected independently from, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 Carbocycle, -CH 2 - (C 3-10 Carbon rings), 3- to 10-membered heterocycles, and -CH 2 - (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), and -OC(O)R 25 It is optionally replaced by one, two, or three elements independently selected from the above, R 21 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles contain halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 22 In each occurrence, H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 3-10 Carbon rings and 3- to 10-membered heterocycles contain halogens and C 1-6 Optionally substituted with one, two, or three groups independently selected from the alkyl group, R 23 In each appearance, H and C 1-6 Selected independently of alkyl, R 24 In each appearance, H and C 1-6 Selected independently of alkyl, R 25 In each occurrence, C 1-6 Alkyl, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-10 A carbon ring and a 3- to 10-membered heterocycle are independently selected, C 1-6 Alkyl, C 3-10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 3-10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with 1, 2, or 3 groups independently selected from these groups. 【Chemistry 4】 The method according to any one of claims 1 to 18, wherein is a single bond or a double bond such that all valencies are satisfied.

20. The method according to any one of claims 1 to 18, wherein the SOS1 inhibitor is selected from BI-3406, MRTX0902, BAY293, RMC-5845, and BI-1701963.

21. The method according to any one of claims 4 to 20, wherein the cancer is lung cancer.

22. The method according to any one of claims 4 to 21, wherein the cancer is non-small cell lung cancer.

23. The method according to any one of claims 4 to 22, wherein the target cancer cells include an EGFR mutation.

24. The method according to claim 23, wherein the EGFR mutation is selected from the L858R mutation, the T790M mutation, the exon 19 deletion, and the exon 20 insertion.

25. The method according to claim 23, wherein the EGFR mutation is an exon 20 insertion.

26. The method according to any one of claims 1 to 25, wherein the target cancer cells include overexpression of MET.

27. The method according to any one of claims 1 to 25, wherein the target cancer cells include MET amplification.

28. The method according to any one of claims 1 to 27, wherein the subject exhibits recurrence of the cancer.

29. The method according to any one of claims 1 to 28, wherein the subject has been previously treated with platinum-based chemotherapy.

30. The method according to any one of claims 1 to 29, wherein the subject has been previously treated with a tyrosine kinase inhibitor (TKI) for EGFR prior to administering (a) and (b).

31. The method according to claim 30, wherein the subject has been previously treated with a non-exon 20 insertion EGFR TKI.

32. The method according to claim 31, wherein the non-exon 20 insertion EGFR TKI is selected from gefitinib, erlotinib, afatinib, razertinib, osimertinib, dacomitinib, neratinib, cetuximab, panitumumab, lapatinib, necitumumab, nazartinib, vandetanib, BLU-945, and zolifertinib.

33. The method according to claim 30, wherein the subject has been previously treated with EGFR exon 20 insertion TKI.

34. The method according to claim 33, wherein the EGFR exon 20 insertion TKI is selected from poziotinib, mobocertinib, amibantamab, diparereltinib, sambozertinib, BAY-2927088, BLU-451, and STX-721.

35. The method according to any one of claims 30 to 34, wherein the subject exhibits resistance or intolerance to the TKI.

36. The method according to claim 35, wherein the resistance to the TKI is characterized by one or more changes selected from (1) cancer progression, (2) EGFR gene mutation, (3) loss of EGFR T790M mutation, (4) EGFR gene amplification, (5) MET amplification, (6) HER2 amplification, (7) RAS-MAPK pathway activation, (8) PI3K pathway activation, (9) cell cycle gene change, (10) oncogenic fusion, (11) histological transformation, and (12) phenotypic transformation.

37. (c) The method according to any one of claims 1 to 36, further comprising administering an additional drug or additional therapy.

38. The method according to claim 37, wherein the additional agent is selected from EGFR TKIs other than osimertinib, immunomodulators, anti-nausea agents, antiemetics, analgesics, steroids, and chemotherapeutic agents.

39. The method according to claim 37, wherein the additional agent is selected from immunomodulators, cytokine blockers, and checkpoint immunoblockers.

40. The method according to claim 37, wherein the additional agent is selected from anti-PD-L1 antibody, anti-CTLA-4 antibody, anti-PD-1 antibody, anti-LAG3 antibody, anti-TIM3 antibody, and combinations thereof.

41. The method according to claim 37, wherein the additional agent is a MET inhibitor.

42. The method according to claim 41, wherein the MET inhibitor is savolitinib.

43. The method according to claim 37, wherein the additional therapy is selected from surgery, cell therapy, chemotherapy, and radiation.

44. The method according to any one of claims 1 to 43, wherein the administration of (a) and (b) reduces the incidence of one or more adverse events associated with osimertinib.

45. The method according to claim 44, wherein the adverse event is selected from diarrhea, rash, nausea, stomatitis, vomiting, paronychia, fatigue, dry skin, loss of appetite, headache, anemia, pneumonia, pruritus, constipation, and cough.

46. The method according to claim 44, wherein the adverse event is selected from diarrhea, rash, nausea, dry skin, and paronychia.

47. The method according to any one of claims 1 to 46, wherein the administration of (a) and (b) exhibits a synergistic effect.

48. The method according to claim 47, wherein the synergistic effect is characterized by a synergistic value of at least 0.05, as confirmed by the Bliss independence criterion.

49. The method according to any one of claims 1 to 48, wherein one or both of (a) and (b) are administered at or below a therapeutic dose, but a therapeutic effect at least comparable to that of administering (a) or (b) alone at a therapeutically effective dose.

50. The method according to any one of claims 1 to 49, wherein osimertinib is administered at a dose of less than approximately 25% of the standard monotherapy dose.

51. The method according to any one of claims 1 to 50, wherein (a) and (b) are administered with the same formulation.

52. The method according to any one of claims 1 to 51, wherein (a) and (b) are administered in a separate formulation.

53. A kit for use in reducing the proliferation of cancer cells containing epidermal growth factor receptor (EGFR) exon 20 insertions, (1) A composition comprising the SOS1 inhibitor of formula (I-1), (2) A composition comprising osimertinib, and (3) A kit including instructions for using the compositions of (1) and (2).

54. The kit according to claim 53, wherein the SOS1 inhibitor and the osimertinib are formulated in the same unit dosage form.

55. The kit according to claim 53, wherein the SOS1 inhibitor and the osimertinib are formulated in different unit dosage forms.

56. A pharmaceutical composition comprising (i) an SOS1 inhibitor of formula (I-1), or a pharmaceutically acceptable salt or solvate thereof, (ii) osimertinib, and (iii) a pharmaceutically acceptable excipient.

57. A method for treating EGFR-mediated cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising (i) an SOS1 inhibitor of formula (I-1) or a pharmaceutically acceptable salt or solvate thereof, (ii) osimertinib, and (iii) a pharmaceutically acceptable excipient.

58. The method according to claim 1, 3, 4, 14, or 57, wherein the subject is a naive subject that has not been treated with a TKI for EGFR prior to administration of (a) and (b).